Antibody-based biosensor assays for the detection of zilpaterol and markers for prostate cancer by Dillon, Mary
Antibody-Based Biosensor Assays For 
The Detection of Zillpatesol and 
Markers for Prostate Cancer 
A thesis submitted for the degree of M.Sc. 
School of Biotechnology, Dublin City University 
Research Supervisor 
Professor Richard O'Kennedy 
School of Biotechnology 
February 2008 
Dedication 
This thesis is dedicated to Mum, to Dad who is no longer with us, and to my family. 
Declaration 
I hereby certify that this material, which I now submit for assessment on the programme 
of study leading to the award of Masters of Science is entirely my own work, that I have 
exercised reasonable care to ensure that the work is original, and does not to the best of 
my knowledge breach any law of copyright, and has not been taken fiom the work of 
others save and to the extent that such work has been cited and acknowledged within the 
text of my work. 
- IDNo.: 531<&533 a t e :  1 1  lo ~ / - ~ 8  
Acknowledgements 
I wish to thank Professor Richard O'Kennedy for his constant support and guidance and 
for his genuine interest in my development. I would also like to thank the lab group with 
whom 1 worked, with special thanks going to Dr. Paul Leonard for his direction and help. 
To my family, I would like to thank them all for their support both financial and 
emotional during my study. 
iii 
Table of Contents 
Dedication 
Declaration 
Acknowledgements 
Abstract 
Abbreviations 
Chapter 1 : Introduction 
1.1. The Immune System 
1.1 .l. Acquired immunity 
1.1.2. Humoral immunity 
1.2. Antibody Structure 
1.2.1. Antibody diversity 
1.3. Antibody technology 
1.3.1. Monoclonal antibody technology 
1.3.2. Recombinant antibodies 
1.3.3. Phage display technology 
1.3.4. Phage antibody libraries and combinatorial libraries 
1.3.5. Expression of recombinant scFv antibodies 
1.3.6. Affinity maturation of scFvs 
1.3.6.1. Site-directed mutagenesis 
1.3.6.2. CDR and chain shuffling 
1.3.6.3. Error prone PCR 
1.3.7. Ribosomal in vitro display 
1.4. Immunoassays 
1.4.1. Enzyme-linked immunosorbent assay (ELISA) 
1.4.2. Biosensors 
1.5. Aims of research 
1 
ii 
iii 
xi 
xii 
Chapter 2: Materials and Methods 31 
2.1. Materials and equipment 32 
2.1.1. Materials 32 
2.1.2. Equipment 33 
2.1.3. Composition of culture media 34 
2.1.4. Buffers 35 
2.2. Characterisation of polyclonal antibodies 36 
2.2.1. Licensing for drug use 36 
2.2.2. Production of zilpaterol-specific polyclonal antibodies 36 
2.2.3. Competitive checkerboard ELISA to determine optimal 
zilpaterol and R699 polyclonal antibody concentrations 36 
2.2.4. Buffer optimisation for R699 polyclonal antibody ELISA 37 
2.2.4.1. Competitive ELISA to determine optimal R699 
polyclonal antibody coating buffer 37 
2.2.4.2. Competitive ELISA to determine optimal 
zilpaterol dilution buffer 37 
2.2.5. Competitive ELISA with R699 polyclonal antibody 37 
2.3. Production of a murine scFv antibody library to zilpaterol 38 
2.3.1. Immunisation and total RNA extraction 38 
2.3.2. Reverse transcription of mouse spleen mRNA 38 
2.3.3. Amplification of antibody light and heavy chain genes 38 
2.3.3.1. PCR primers 38 
2.3.3.2. PCR amplification of light and heavy chain genes 40 
2.3.3.3. PCR conditions for amplification of light and 
heavy chain genes 41 
2.3.3.4. Purification of PCR reaction products 41 
2.3.3.5. Quantification of purified PCR products 42 
2.3.4. Components of splice by overlap extention (SOE) PCR 42 
2.3.4.1. SOE-PCR conditions for amplification of joined 
antibody light and heavy chain genes 43 
2.3.5. Preparation and purification of pAKlOO vector using 
Wizard miniprep system (Promega) 43 
2.3.6. Digestion of pAKlOO and antibody light and heavy chain 
genes SOE-PCR products 45 
2.3.7. Ligation of antibody light and heavy chain genes into the 
pAK 100 vector 45 
2.3.8. Preparation of high efficiency competent cells 46 
2.3.9. Transformation of E. coli XL1-Blue competent cells with 
pAK 100 vector containing light and heavy chain genes 
and measurement of transformation efficiencies 46 
2.4. Production of scFv antibodies to zilpaterol 47 
2.4.1. Rescue of scFv displaying phage 47 
2.4.2. PEG/NaCI precipitation 47 
2.4.3. Phage titre 48 
2.4.4. Affinity selection of antigen binders by biopanning 48 
2.4.5. Reinfection of phage displaying scFv antibodies 48 
2.4.6. Preparation of clones for phage ELISA 49 
2.4.7. ELISA of phage-displayed scFv antibodies 49 
2.4.8. Preparation of bacterial glycerol stocks 50 
2.4.9. Isolation of the scFv gene from the pAKlOO vector within 
the positive clones 50 
2.4.10. Ligation of scFv gene into pAK400 for soluble scFv 
antibody expression 51 
2.4.1 1. Preparation of competent E. coli JM83 bacterial cells 51 
2.4.12. Transformation of E. coli JM83 competent cells with 
pAK400 vector 51 
2.4.13. Soluble expression of scFv antibodies Erom JM83 cells 
containing the pAK400 vector with scFv gene insert 51 
2.4.14. Non-competitive ELISA for the determination of soluble 
scFv 52 
2.4.15. Checkerboard ELISA for determination of the optimal 
concentrations of immobilised zilpaterol-HSA conjugate 
and scFv antibody dilution for generation of a competitive 
ELISA 52 
2.4.16. Competitive ELISA for soluble scFv antibody 
characterisation 53 
2.5. Cloning of the gene sequences encoding PSA and E. coli 
2.5.1. Preparation of PSA gene 
2.5.2. Transformation of PSA.pcDNA3 vector into E. coli JM83 
cells 
2.5.3. Isolation of PSA gene 
2.5.4. PCR amplification of PSA gene 
2.5.5. Purification of PCR reaction products 
2.5.6. Quantification of purified PCR products 
2.6. Inhibition ELISA for the detection of recombinant PSA 
2.7. Development of SPR-based immunoassay using a Biacore 3000 
Instrument 
2.7.1. Preconcentration studies 
2.7.2. Immobilisation ofprotein G 
2.7.3. Inhibition immunoassay for the detection of zilpaterol 
using R699 anti-zilpaterol polyclonal antibody 
2.7.4. Inhibition immunoassay for the detection of zilpaterol 
using the anti-zilpaterol scFv antibody 
Chapter 3: Production and Application of Polyclonal Antibodies and scFv 
Antibody fragments to Zilpaterol 59 
3.1. Introduction 60 
3.1.1. The beta-agonists 
3.1.2. Zilpaterol 
3.1.3. Detection of zilpaterol 
3.2. Results 
3.2.1. Development of a competitive enzyme-linked 
immunosorbent assay (ELISA) for zilpaterol 
3.2.1.1. Competitive checkerboard ELISA of R699 
polyclonal antibody to determine optimal antibody 
and zilpaterol concentrations 66 
3.2.1.2. Polyclonal antibody ELISA buffer optimization 66 
3.2.1.2.1. Competitive ELISA to determine 
optimal coating buffer 66 
3.2.1.2.2. Competitive ELISA to determine 
optimal zilpaterol dilution buffer 66 
3.2.1.3. Development of a competitive ELISA for the 
detection of zilpaterol 67 
3.2.2. Cross-reactivity studies 72 
3.2.3. Development of a Biacore-based inhibition irnmunoassay 
for zilpaterol 75 
3.2.3.1. CM5 Biacore chip directly immobilised with 
zilpaterol 75 
3.2.3.2. Inhibition immunoassay for the detection of 
zilpaterol using R699 anti-zilpaterol polyclonal 
antibody 75 
3.2.4. The production of a murine scFv antibody library to 
zilpaterol 78 
3.2.4.1. Immunisation of mice with zilpaterol-HSA and 
isolation of spleenocyte mFWA 78 
3.2.4.2. Reverse transcription of mouse spleen mRNA 78 
3.2.4.3. Amplification of antibody light and heavy chain 
genes 78 
3.2.4.4. Splice by overlap extension (SOE) PCR 
3.2.4.5. Digestion of pAK100 vector and SOE-PCR 
products formed by linking antibody light and 
heavy chain genes 
3.2.4.6. Ligation of antibody light and heavy chain 
genes into the pAK 100 vector 
3.2.4.7. Transformation of E. coli XL1-Blue 
supercompetent cells with pAK 100 vector 
containing light and heavy chain gene 
3.2.5. Production of single chain Fv antibodies to zilpaterol 
3.2.5.1. First round selection and screening of hctional 
scFv sequences to zilpaterol &om zilpaterol 
recombinant library using phage ELISA 
3.2.5.2. Digestion of A9, Bl, E2 and E7 scFv 
antibody light and heavy chain genes and 
pAK 400 vector for production of soluble scFv 
antibody 
3.2.5.3. Soluble expression of A9, Bl, E2 and E7 scFv 
antibodies 
3.2.6. Development of an scFv-based competitive enzyme- 
linked immunosorbent assay(EL1SA) for zilpaterol 
3.2.6.1. Checkerboard ELISA for determination of 
optimal zilpaterol coating concentration and 
optimal scFv antibody dilution 
3.2.6.2. Interday competitive ELISA for Bl  scFv 
antibody characterization 
3.2.7. Development of a Biacore-based inhibition irnmunoassay 
for zilpaterol 
3.2.7.1. CM5 Biacore chip directly immobilised with 
zilpaterol 
3.2.7.2. Inhibition immunoassay for the detection of 
zilpaterol using the anti-zilpaterol scFv antibody 91 
3.2.7.3. Biacore-based cross-reactivity study of scFv 
antibody 91 
3.3. Discussion 96 
Chapter 4: Cloning, expression and purification of a recombinant form 
of prostate-specific antigen protein 
4.1. Introduction 
4.1.1. Prostate-specific antigen 
4.1.2. ELISA development for PSA detection 
4.2. Results 
4.2.1. Transfer of PSA gene insert into pQE-60 vector 
4.2.2. Reamplification of PSA gene, ligation into pQE-60 
and transformation into XL-10 Gold 
4.2.3. Time course analysis of PSA expression 
4.2.4. Immobilised metal affinity chromatography (IMAC) 
purification of PSA 
4.2.5. Development of a competitive enzyme-linked 
immunosorbent assay (ELISA) for PSA 
4.3. Conclusion 
Chapter 5: Overall conclusion 
Chapter 6: Reference 
Antibody-Based Biosensor Assays for the Detection of Zilpaterol and Markers for 
Prostate Cancer 
Mary Dillon 
Abstract 
The research presented in this thesis describes the production and application of 
antibodies against the drug of abuse zilpaterol, and the application of antibodies against 
prostate-specific antigen (PSA), a cancer marker. 
Polyclonal antibodies were used in the development of immunoassays in a competitive 
ELISA format and on the Biacore (a surface plasmon resonance-based optical biosensor 
capable of monitoring biomolecular interactions in 'real-time'). 
A zilpaterol-HSA conjugate was used to generate and characterise single chain antibody 
fragments. A combinatorial single chain (scFv) antibody phage display library was 
generated to zilpaterol. Splenomic mRNA from mice pre-immunised with a zilpaterol- 
HSA conjugate was used in the amplification of antibody genes followed by cloning into 
vectors from a well-established phage display system. Four positive clones were isolated 
during panning. One clone (Bl) was selected and re-cloned into a plasmid fiom soluble 
scFv antibody expression. The soluble scFv antibody was purified and used in the 
development of a competitive ELISA-based assay. Further analysis of the B 1 clone was 
carried out during the development of an inhibition assay for zilpaterol on Biacore. 
Affinity determinations of the scFv antibody for zilpaterol were carried out using 'real- 
time' biomolecular interaction analysis. 
A recombinant form of PSA was also produced and characterised. Commercial anti-PSA 
antibodies were used to generate a competitive ELISA. 
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Chapter 1 
Introduction 
1.1 The Immune System 
The mammalian immune system consists of a range of mechanisms aimed at 
removing foreign entities such as bacteria, viruses, fungi and parasites that might 
prove hannful to the body. The immune system consists of two distinct mechanisms 
of defence, innate immunity and acquired immunity. Innate immunity consists of a 
series of physical and chemical barriers and non-specific cell-mediated responses. It 
has an immediate effect on foreign materials, and is not enhanced through repeated 
exposure to the same foreign body. Innate immunity functions on two levels; primary 
and secondary. 
The primary defence mechanism includes the skin and mucous membranes; the 
former acting as a barrier against microbial invasion, the latter allowing for the 
entrapment and elimination of foreign bodies. The secondary line of defence 
involved in innate immunity consists of cell-mediated non-specific responses to 
foreign cells and includes such internal systems as phagocytosis by macrophages and 
cell lysis by natural killer (NK) cells. Phagocytes are derived from bone marrow stem 
cells. They engulf and ingest foreign bodies, and are present in areas most likely to 
encounter foreign bodies. Natural killer cells have the ability to recognise infected 
somatic cells based on cell-surface changes, i.e. viral infection. They then bind the 
infected cells and destroy them by inducing apoptosis. 
1.1.1 Acquired immunity 
Acquired immunity refers to the mechanisms of the immune response that are capable 
of adapting themselves to previously unseen molecules, producing specific memory 
cells that can act specifically to prevent further infection. There are two types of 
acquired immunity, humoral and cell-mediated. Humoral immunity involves B- 
lymphocytes producing antigen-specific molecules called antibodies. The coating of 
an antigen with antibodies results in the attraction of proteins, such as those of the 
complement system, that rupture the bacterial cell and, ultimately, engulfing of the 
antigen by phagocytes that digests the foreign cell. Cell-mediated immunity targets 
intracellular pathogens through recognition and elimination of infected somatic cells 
displaying surface antigen associated with the pathogen. The cells involved in this 
response are mainly cytotoxic T-cells (Tc) derived fiom activated T-lymphocytes in 
the thymus (Elliott and Elliott, 2001). In general, while humoral and cell-mediated 
immunity function separately, elements of both types of acquired immunity also 
interact to facilitate for complete activation of the immune response. 
All nucleated cells of the body that have been infected by a virus display antigen on 
their surfaces associated with proteins of the Major Histocompatability Complex class 
I (MHC I). These proteins are recognised by Tc cells. Tc cell recognition of the 
antigens results in signalling that causes the cell to become apoptotic, killing both the 
cell and m y  intracellular pathogens. Each Tc cell contains granules consisting of 
perforin and a set of serine proteases called granzymes, which when released, also 
result in death of the infected cell. Perforin causes lysis of the infected cell, 
facilitating the entry of granzymes and causes eventual cell death. Tc cells also 
release cytokines, such as y-interferon that reduce the spread of the virus to adjacent 
cells (Male et al., 1996). 
Following exposure to an antigen, macrophages engulf, process and present the 
antigen on the surface of the cell via the Major Histocompatability Complex class I1 
(MHC 11) proteins. Such cells are known as antigen presenting cells (APC), and it is 
the antigens displayed on the surface of these cells to which the helper T-cell 
receptors bind. There are two subsets of TH cells, TH1 and TH2, which are primarily 
different due to the cytokines they produce. T"1 cells recognise antigens presented on 
the surface of macrophages and subsequently produce y-interferon and tumour 
necrosis factor beta (TNF-P), which are mainly responsible for activation of Tc cells, 
natural killer cells and macrophages. T H ~  cells secrete cytokines such as interleukins 
4, 5, 10 and 13 and their main function is the activation of B-lymphocytes (Roitt et 
al., 1998). 
1.1.2. Humoral immunity 
Antibodies produced by B-lymphocytes mediate the humoral immune response. The 
interaction between B-lymphocytes and TH2 cells is of critical importance for the 
production of antigen-specific antibodies. Immature B-lymphocytes are formed in the 
bone marrow and have the potential to produce antibodies to attack virtually every 
macromolecule present in the body. Those B-lymphocytes that produce antibodies 
against a bodily protein (a self-protein) are eliminated during primary maturation. In 
response to other foreign antigens present, each B-lymphocyte displays a membrane- 
bound immunoglobulin with a single specificity, on its surface, which acts as an 
antigen receptor. Binding of the antigen to the cells displaying antibodies with the 
highest specificity for the antigen, results in internalisation and surface display of that 
antigen. It is at this stage that T H ~  cells, already activated though contact with an 
APC, recognise and bind specifically to B-lymphocytes displaying the same antigen. 
Their combination causes cytokine production, which results in B-cell multiplication 
and differentiation into antibody-secreting plasma cells. The types of cytokines 
secreted by the TH cell determine the class of immunoglobulin produced. 
Upon B-lymphocyte activation and proliferation, a proportion of the resulting clones 
mature into long-lived memory cells that can circulate for years. These cells form the 
basis of long-term immunity in the event of repeated infection. If the same antigen is 
encountered again, a much more rapid immune response is generated. 
1.2 Antibody structure 
Antibodies are a group of glycoproteins present in the serum of mammals, and are 
involved in immunity. Upon infection of the body by a foreign antigen, an immune 
response in initiated. Through contact of the antigen with B-cells and subsequent 
differentiation of the B-cells into plasma cells, antibodies specific for the antigen are 
secreted to aid in its elimination from the body. This differentiation of B-cells leads 
to the production of multiple different antibodies, all with varying affinity and 
specificity to the antigen (De Franco, 1999). Antibody affmity can be further 
improved by the process of affinity maturation within the producer cells, involving 
somatic hypermutation of the amino acid sequence of the CDR (complementarity 
determining region) of the variable heavy and light chains. This results in increased 
production of antibodies demonstrating new binding &nities, a minority of which 
will show affinities higher than that of the pre-maturation antibodies. These are 
selectively amplified. The growth of these clones is encouraged, while the growth of 
cells producing antibodies of low affinity ceases. The continuation of this process 
within the body's immune system results in the active production, selection and 
amplification of highly specific antibodies towards the target antigen (Berek, 1999). 
Antibodies (immunoglobulins) are highly soluble glycoproteins. The basic structure 
of an antibody e.g. IgG (Figure 1.1) consists of four polypeptide chains with two 
identical heavy chains (H) and two identical light chains (L) l i e d  by disulphide 
bonds. This structure can vary depending on the isotype. The amino terminal ends of 
both heavy and light antibody chains are characterised by variability of the sequence. 
These areas are known as VH and VL regions. Constant regions (CH and CL) are 
located further downstream. Disulphide bonds link the two heavy chains by the 
constant regions, as shown in Figure 1.1. The hinge region consists of an area 
containing a higher number of proline residues, which allows movement of the two 
Fab regions between 60' and 180'. This aspect confers many desirable characteristics 
upon the activity of the antibody. It allows the 2 binding sites to work independently 
of each other, and facilitates binding of the antibody to a wide range of sites of 
varying size and conformation on the antigen surface (Frazer and Capra, 1999). 
Several highly variable areas are present in each chain within the variable regions of 
the antibody light and heavy chains. It is these regions that confer most of the 
antigenic recognition, specificity and affmity. These hypervariable regions are 
collectively known as complementary determining regions (CDRs). They consist of 
approximately 110 amino acids, interspersed by constant areas called framework 
regions (FR). The FRs provide a backbone structure for the antibody, and can also 
have an influence on antigenic specificity. The conformation of the light and heavy 
chain CDRs result in six hypervariable loop structures which structurally form 
antigen-binding surfaces or pockets (Branden and Tooze, 1998) (Figure 1.1). 
, \  CDR regions 
disulphide bonds Disulphide bonds 
Figure 1.1 Diagrammatic representation of an immunoglobulin G (IgG) molecule. The IgG antibody 
consists of two identical heay chains and two identical light chains. Each chain consists of a variable 
region at the amino terminal end, referred to as variable heay  (Y,j and variable light CY3. 
respectively. The remainder of the light chain is called the constant region (Cd. The constant region 
of the heavy chain is longer and is divided into three separate regions, CHI, Cx2 and Cx3. Interchain 
and inhachain disulphide bonak link the heavy and light chains. The variable regions of the heavy and 
light chains contain the CDR regions, which confer antigen specifcity on the antibody. A hinge region 
also exists between the CHI and Cx2 domains that allow conformationa changes to occur in the 
antibody resulting inflenibiliiy of between 60' and 1804 
1.2.1 Antibody diversity 
The capability of the body to generate an enormous diversity of antibodies accounts 
for the remarkably adaptive nature of the immune system. It is because of the unique 
genetic mechanisms governing antibody synthesis that the body is capable of 
producing these highly specific molecules to previously unknown agents. This 
diversity is mainly confined to the heavy and light chain variable regions and, more 
specifically, the CDRs, and can be attributed to mechanisms such as the specialised 
replication of the antibody light and heavy chain germline genes, clonal selection and 
somatic mutation (Tizard, 1995). 
Variable light chain genes are composed of two loci, the V (variable) and J (joining) 
loci, while heavy chain gene sequences are composed of three loci; the V and J loci 
with an additional D (diversity) locus. During B-cell maturation, these different 
regions combine randomly to produce the diversity observed. Recombination of the 
various VDJ sequences on the heavy chain and the VJ sequences on the light chain 
results in the formation of different structural conformations in the binding sites of the 
resulting antibodies (Max, 1999). 
Binding site diversity can be further enhanced through various adaptations in the 
bases between gene segments. Mutations including the insertion, deletion and 
copying of bases within the genes, result in additional variation in the amino acid 
sequence of the antibody binding sites. This added diversity, called junctional 
diversity, further increases the variety of antibodies generated. Point mutations occur 
frequently in this region and also increase antibody diversity. The combined result of 
all these mechanisms is the ability of the body to produce antibodies with potential 
specificity for almost any antigen (Max, 1999). 
1.3 Antibody technology 
1.3.1 Monoclonal antibody technology 
Initially, all antibodies available for analysis originated from the serum of immunised 
animals and were polyclonal in nature. Polyclonal antibodies consist of a mixture of 
antibodies to both the antigen of interest and to unrelated antigens naturally found in 
the host. Such antibodies may have a range of affinities and specificities (Kane and 
Banks, 2000). There are several advantages associated with the use of polyclonal 
antibodies in immunoassays. Polyclonal antibodies can demonstrate high specificity, 
despite the fact that their affinities and specificities may widely vary. This is because 
polyclonal antibodies may potentially include antibodies that can bind to multiple 
different sites on the antigen surface, and may be particularly useful in the initial 
detection of a previously unknown molecule (Mayforth, 1993). In addition, their 
production requires a minimum of technical input relative to that necessary for 
monoclonal or recombinant antibody generation (Dean and Shepherd, 2000). 
Monoclonal antibodies, unlike polyclonal, are a homogenous population of antibodies 
derived from a single antibody-producing cell. Hence, all antibodies are identic& and 
of the same precise specificity for a defined epitope (Kohler and Milstein, 1975; 
Delves, 1997; Kane and Banks, 2000). Since the antibody is the product of a single 
cell line, it is possible to produce unlimited amounts, as long as the source cell line is 
maintained. This contrasts with polyclonal antibody production whereby antibody 
quantity is limited by the animal. In addition, the use of a homogenous antibody 
preparation results in elimination of assay variation and leads to significant increases 
in assay reliability (Nelson et al., 2000). 
Monoclonal antibody production begins with immunisation of a host animal with the 
required antigen (Figure 1.2). Once a sufficient antibody response is generated, the 
animal is sacrificed and the spleen removed. Primed B-cells are then fused to 
myeloma cells (tumorigenic B-lymphocytes) in order to confer immortality upon the 
antibody-producing B-cell. Fusion of the cells is facilitated by the use of 
polyethylene glycol (PEG) and other methods, which promote membrane bridging 
and transfer of nuclei (Hurrell, 1985). 
Fusion of the myeloma and B-cells is carried out in HAT medium (media containing 
Hypoxanthine, Aminopterin and Thymidine). Aminopterin prevents the formation of 
tetrahydrofolate, which is necessary for thymidine synthesis. Therefore, the 
formation of dGTP, dATP and dTTP is inhibited and, subsequently, de novo synthesis 
of DNA is blocked. A salvage pathway capable of using hypoxanthine and the 
enzyme, Hypoxanthine Guanidine Phosophoribosyl Transferase (HGPRT), is present. 
However, the myleoma cells are selected that specifically lack HGPRT and are, 
therefore, incapable of using this pathway. These myeloma cells cannot reproduce 
since they cannot use either pathway and subsequently die in culture. However, since 
the spleen cells do not lack the enzyme, they are capable of DNA synthesis via the 
salvage pathway. Hence, when the myeloma and B-cells fuse, the resulting 
hybridoma is capable of DNA synthesis and is immortal. Any remaining B-cells that 
did not form hybridomas are unable to proliferate, since somatic cells cannot grow 
continuously outside the body, and die. The unfused myleoma cells cannot synthesise 
DNA in HAT medium. Therefore, only the hybridoma cells will grow (Figure 1.2), 
resulting in an immortal cell line with the potential for monoclonal antibody 
production (Kohler and Milstein, 1975; King, 1998; Dean and Shepherd, 2000; 
Stapleton ef al., 2004). The antibody-producing clones are then screened by enzyme- 
linked imrnunoassay (ELISA) and antibodies with the required characteristics 
selected. 
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Figure 1.2 Principles of monoclonal antiboQproduction 
Specialised myeloma cells and spleenocyte cells extractedfrom an immunised mouse are incubated 
with polyethylene glycol (PEG) to facilitate their @ion. HAT media contains Hypoxonthine, 
Aminopterin and Thymidine and block de novo DNA synthesis. Since the myeloma cells chosen 
spec@cally lack the salvage pathway of DNA synrhesis, they cannot grow in this media. Subsequent 
addition of HAT to the media eliminates unfised myeloma cells from the culture. Since somatic cells 
cannot survive for long in culture, @ed hybrihma cells are selected The remaining cells are 
screened by ELlSA for the production of monoclonal antibodies specifc for the required antigen. 
The selected antibodies are then characterised and, subsequently, purzfied 
b 
1.3.2 Recombinant antibodies 
Recombinant techniques have facilitated the generation of specifically engineered 
antibody fragments that have been successfully employed in immunoassays (Dillon et 
al., 2002; Brennan et al., 2003; BIazek et al., 2004). Functional antibody fragments 
consist of various chains of the antibody, i.e. the whole antibody minus some of the 
structural regions that still display the specificity and affinity properties of the whole 
antibody molecule. 
Figure 1.3 (b, c and d) illustrates some of the recombinant antibody fiagments used in 
immunoassay development. These fragments are named after the specific section of 
1 
the antibody from which they are derived (Smith, 1985). The Fc region of the 
antibody consists of the two constant chains l i e d  with inter-chain disulphide bonds. 
Very useful ssmaller fragments can also be engineered. The Fab fragment consists of 
the light and the corresponding heavy chains of one arm of the antibody (Figure 1.3 
b), and as with a complete antibody, the specificity of this fragment is dictated by the 
variable region. Stability is maintained as a result of the inhachain disulphide bond 
which l i d s  the heavy and light chains. The Fv (variable fragment) is smaller and is 
comprised of only the variable light and heavy chains of one arm of the antibody 
(Figure 1.3 c). The advantages of this fragment axe due to its small size, and its 
retention of almost 100% of the specificity of the whole antibody from which it was 
derived, since the binding sites remain intact. However, this hgment lacks stability, 
due to the absence of a disulphide bond l i n g  the two chains (Killard et al., 1995; 
Liddell, 2001). A new variation on this fragment has emerged and has become a 
significant alternative. The scFv, or single chain variable fragment, consists of the 
heavy and light chain variable regions joined by a 15-20 amino-acid linker peptide 
(usually a glycine-serine repeat linker) molecule (Figure 1.3 d). This linker does not 
interfere with the biding capacity of the scFv and confers stability on the molecule 
(Hudson, 1998; Gosling, 2000). The versatility of scFv antibody fragments has led to 
use of methods such as phage display for easier antibody selection. 
Antigen I 
binding site 
Disulphide bonds 
U u 
Figure 1.3 ZIlustration of an IgG antibody and antibodyfragments. 
(a) Whole IgG antibody 
(8) Fab is a complete arm of the antibody including the variable regions of the heavy and light chains, 
the constant region of the light chain and the corresponding heavy chain region. The disulphide bond 
of the antibody holdr the chains together. 
(c) The Fv, or variable fragment, consists of the variable regions of both heavy and light chains. 
(d) ScFv, or single-chain variable fragment, consists of the Fvfragment made stable by the addition of 
a linker molecule between the Vx and VL regions. 
1.3.3 Phage display technology 
Phage display refers to the display of functional foreign peptides or small proteins on 
the surface of bacteriophage (Smith, 1985). Phage display is recognised as a powerful 
way in which to screen and select peptides on the basis of binding or molecular 
recognition. For diagnostic immunologists, the most important advantage of this 
technique is the ability to directly select the genetic information coding the most 
highly-specific antibodies. It also allows optimal antibody selection from unbiased 
libraries with more speed and accuracy than other methods (Osborn, 2000). 
Viruses are extremely small parasites that require a host cell for replication. Virus 
particles essentially comprise of a nucleic acid genome and protein coat. 
Bacteriophage (or phage) refer to viruses that infect bacteria. The replication of 
bacteriophage can be roughly divided into two types; lytic, involving lysis of the host 
cell upon particle release, and non-lytic, where release of the phage particles does not 
result in cell death. 
Various functional peptides can be displayed on the surfaces of viruses such as 
bacteriophage A, the tobacco mosaic virus, herpes simplex virus, baculovirus and 
hepatitis B virus (Yau et al., 2003). For affmity selection, however, the most 
commonly used virus is the Escherichia coli-specific filamentous phage, including 
M13, fd and fl (Hoogenboom et al., 1992). Filamentous phage contain a circular 
single-stranded DNA genome contained within a protein capsid cylmder. 
Filamentous phage do not reproduce by the traditional lytic cycle, but propagate 
within the bacterial cell and are secreted without lysis of the cell. Each infected cell is 
capable of producing over a thousand phage particles. 
Filamentous phage are covered by approximately 3000 coat proteins present on the 
filament surface. The major coat protein pVIII (approximately 2700 copies per phage 
particle) covers most of the surface. The minor coat proteins, pIII, pVI, pVII and pIX 
are displayed at either extremity of the filament. All of these coat proteins have been 
used for displaying peptides on the phage surface. However, pIII is most frequently 
used for antibody fragment display. Each pIII consists of 406 amino acids (excluding 
the leader sequence) hooked to the virion surface at the carboxy terminus. The region 
of pII1 between this and the N-terminal domain is required for attachment and 
penetration of the bacterial cell during infection. Foreign peptides are covalently 
linked to the free amino ends of this coat protein, as shown in Figure 1.4. This allows 
the coat protein to remain functional and infection capabilities of the particle are not 
significantly impaired (Smith, 1985; O m  et al., 1993). 
The principle of phage display for antibody selection, therefore, is to successfully 
display the antibody or antibody fragment on the surface of the phage by integrating 
its genetic information into the sequence coding for the pIII protein. This is done 
using either a phage vector or a phagemid vector. Several different types of these 
vectors are available. Complete phage vectors or bacteriophage carry all the genetic 
information required for the phage life cycle (Hoogenboom et al., 1998). However, 
more recently, phagemid systems that have been developed for phage display are 
used. Phagemids were originally derived from an expression vector engineered to 
express the foreign peptide as a fusion of the N-terminus of the phage coat protein. 
They contain the origins of replication for both the M13 phage and E. coli bacteria in 
addition to gene 111. They also contain multiple cloning sites and an antibiotic- 
resistance gene, but no other gene products required for generating a complete phage. 
When a bacterial cell harbouring the phagemid vector is super-infected with a helper 
phage such as M13K07, the protein synthesis machinery of the host is used to produce 
all the wild type phage proteins (from the helper phage genome) plus the antibody- 
phage coat fusion protein (from the phagemid vector). When new phage particles are 
assembled, single stranded DNA from the phagemid bearing the fusion peptide gene 
will be packaged, while the encoded fusion protein will be displayed on the surface of 
the phage particle (Osbourn, 2000; Liddell, 2001). The advantages of the use of a 
phagemid vector in comparison to phage vectors include the smaller size and the 
higher bacterial transformation efficiency observed with the phagemid vector. In 
addition, phagemid display promotes the monovalent display of antibody particles, 
resulting in selection based on affinity of the antibody rather than cumulative avidity 
(MacKenzie and To, 1998; Tout et al., 2001). 
D ScFv displayed as 
> part of plll surface 
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Figure 1.4 A filamentous phage purtikle. A scFv fragment is displayed as part of the pIU coat 
protein present on the Jilamentous phage surface. The phagemid vector within the phage pmficle 
contains the variable heavy und light chain geneshed with thep1.U gene, an ampicillin resistance 
gene and origins of replication for both MI3 helper phage and E. coli. 
Col El ori: E. coli origin of replication gene 
AMP': ampicillin resistance gene 
MI3 ori: MI3 phagemid origin of replication gene 
1.3.4 Phage antibody libraries and eombinatorial libraries 
A number of antibody-producing cells can be used as the starting material for the 
construction of a phage display library. These include hybridoma cells, splenocytes 
or lymphocytes from bone marrow or blood. Affinity selection of antibody fragments 
displayed on the surface of phage can replace the time-consuming and labour- 
intensive procedure of hybridoma production. The initial step involves mRNA 
extraction and the use of PCR to amplify the antibody genes in vitro. Specific heavy 
and light chain primers are used to separately synthesise the variable regions of the 
heavy (VH) and light (VL) chain genes of the antibody using the template produced 
from the cells. Once obtained, these heavy and light genes can be artificially paired 
through splice by overlap extention (SOE) PCR, a technique in which the genes are 
joined through the use of each heavy and light chain gene as a primer for the other, 
and then amplification of the product. The antibody fragment genes are then ligated 
into the digested vector and transformed into E. coli. In this way, a random 
combinatorial library is created (Krebber et al., 1997) (Figure 1.5). If a library size of 
lo8 members or more is obtained, all possible VH& pairings, includmg the pairs 
originating from B cells selected by the immune system, are present. Subsequently, 
the library of recombinant antibody fragments may be displayed on phage and 
functionally selected against the target antigen. 
Aflhity selection of the scFv by panning and subsequent reinfection into E. coli 
greatly enhances the number of strong binding scFvs. Panning of the phage library 
involves the passing of the hagment-displaying phage over a surface coated with the 
antigen in question. Unbound phage i.e. particles not displaying antigen-specific 
fragments, are washed away. Remaining phage are then eluted and used to reinfect E. 
coli cells. After several rounds of panning are completed, only the most high affinity 
antigen-specific fragments remain (Liddell, 2001). Phage display scFvs and Fabs 
with comparable or better affinities and specificities to monoclonal antibodies can be 
isolated (Figure 1.6). 
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Figure 1.5 Construction of aphage display library. mRNA is extractedfrom an immunised animal and 
PCR used to amplz& the antibo& genes in vitro. The variable regions of the heavy (Vlt) and light 
chain genes of the antibo4y me amplified using the template producedfrom the cells, then artificially 
paired through splice by overlap extension (SOE) PCR The antibo&fragment genes are then ligated 
into the digested vector and tramformed into E. coli. In this way, a random combinatorial library is 
created 
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Figure 1.6 Procedure for selection of specific scFv-dsplayingphage from phage libraries. A phage 
library [I] is passed over an antigen-coated sw$ace and phage displaying antigen-specgc scFvs 
bind to the surface [2]. Any unboundphage are washed away [3]. Specific library phage are then 
eluted [4] and subsequently analysed [5] and reinfcted into E. coli for amplifiation and rescue [6]. 
l%ispanningprocess is repeatedfor severalfirrther rounds. Enrichment of antigen-specficphage is 
achieved a@r each round ofpanning. 
1.3.5 Expression of recombinant scFv antibodies 
Bacterial expression systems are commonly used for the production of all functional 
antibody fragments, due to the rapid and inexpensive fermentation of bacteria, ease of 
genetic manipulation and the fact that antibody fragments do not require post- 
translational modification. 
Antibody fragments that have been selected while displayed on the surface of a phage 
particle can be produced in a soluble form. The gene sequence coding for the 
fragment can be ligated into a phagemid that contains an amber stop codon and a 
leader sequence. The amber stop codon is located on the phagemid between the scFv 
gene and the gIII gene, encoding the pIII phage coat protein. In non-supressor strains 
of E, coli, such as HI32151 and JM83, this amber codon is recognised as a stop codon. 
This halts transcription and results in secretion of soluble antibody. 
The leader sequence, which has also been translated, directs the expressed scFv into 
the periplasmic space of E. coli. This sequence is cleaved during transport through 
the membrane allowing the correct folding of the antibody for expression. 
1.3.6 M i i t y  maturation of scFvs 
Once an antibody or antibody fragment specific for a given antigen has been isolated, 
improvement of the affinity of that antibody is often desirable. Antibody affinity can 
be improved in vilro using a variety of techniques including site-directed mutagenesis, 
CDR shuffling, chain shuffling or error-prone PCR. The effects of these mutations is 
then analysed by the process of selection and screening. 
1.3.6.1 Site-directed mutagenesis 
Site-directed mutagenesis involves the specific mutation of one or more amino acids 
present in the antibody sequence (mainly the CDR regions), and subsequent selection 
of antibodies demonstrating higher affinities. 
1.3.6.2 CDR and chain shuffling 
Chain shuffling mutagenesis is the isolation and pairing of the optimal VH and VL 
chains &om an antibody library in order to select the most specific antibody possible 
from that library. The process involves recloning of one gene for one chain of the 
scFv (e.g. VH), with a repertoire of genes for the other chain (VL) (Marks et al., 1992). 
The resulting antibody library consists of phage encoding an scFv containing Va 
chains specific for the target antigen and random VL chains. This library is screened 
for specific binders and the clones that produce scFvs displaying improved binding 
properties are identified. These VL chain genes are then fixed, and cloned along with 
the repertoire of genes for the VH chain. In many cases, in order to maintain the 
specificity of the parent scFv, the CDR H3 may be kept constant to retain specificity, 
and only frameworks 1 to 3 of the variable chain segment are replaced. 
1.3.6.3 Error prone PCR 
Error prone PCR involves the introduction of mutations during PCR amplification of 
the antibody gene fragment in an attempt to increase antibody affinity. One method 
involves the use of DNA polymerases that lack proof-reading capabilities, resulting in 
random insertions, deletions and substitutions of the gene sequence. Panning of the 
resulting library is conducted and the affinity of the positive clones isolated is 
compared to that of the wild type. 
1.3.7 Ribosomal in vitro display 
Ribosomal and mRNA in vitro display technologies are established as the alternatives 
to phage display for the isolation of specific antibody fragments with direct linkage to 
the DNA encodmg that fragment. Phage display is a cell-dependent system, a fact 
that limits cellular transformation efficiencies and subsequent library size. In virro 
systems have no such limits and can therefore yield much larger libraries. Selection 
disadvantages of host environments (i.e. host bacterial cells used in phage display) 
against specific scFvs also do not occur in such "cell flee" systems. Ribosomal and 
mRNA antibody display also facilitate direct protein evolution (Figure 1.7). 
I 
Ribosomal display was first developed in 1994 (Mattheakis et al., 1994), and involves 
the in vitro transcription of the scFv fiagment of interest, followed by in vitro 
translation, whereby the mRNA is retained on the ribosome by the absence of a stop 
codon. With no stop codon, protein elongation stops. However, the ribosome 
remains complexed to the mRNA. In addition, certain polypeptide releasing factors 
are not present and the nascent antibody remains attached to the ribosome. Therefore, 
through the ribosome, the antibody fragment remains attached to its encoding 
nueleotide sequence (Hanes and Pluckthun, 1997; He and Taussig, 1997). The 
complex is stabilised at low temperature (4 '~)  and in buffer containing magnesium, 
then affinity selected from the translation mixture through binding of the native scFv 
I to the specific immobilised antigen. Non-specific binders are eliminated following 
stringent wash steps and specific binders are eluted by dissociation with EDTA or 
upon addition of free antigen (Hanes and Pluckthun, 1997). In this way the mRNA 
coding for the most specific antibody fragment can be isolated and reverse transcribed 
into cDNA for use in the next enrichment cycle. 
Pluckthun and colleagues have studied complexes of mRNA-ribosome-protein 
systhesised by E. coli extract. They demonstrated that ribosomal display could select 
and enrich high affinity biders from a library and could also provide in vitro 
hypermutation to evolve the selected clones (Hanes et al., 2000). In their 
experiments, insulin-specific scFv fragments were selected from the synthetic ndive 
human combinatorial antibody library (HuCal). After six rounds of selection, strong 
binders with dissociation constants in low nanomolar to picomolar ranges were 
isolated, with the lowest Kd being 82 pM. Sequence analysis indicated that certain 
specific mutations were identified in some of the sequences that contributed to the 
high affmities seen in these binders. 
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Figure I. 7 Selechchon of scFv anti%a& fragmtm3 using ribosomal dispI4y. Double-stranded DNA 
constructs are transcribed and translated in vitro. The ribosome stalls at the end of each transcript 
due to the h e n c e  of a stop rodon, forming a ribosodisployed scFv c o m p l ~  consisting of the 
mRNA, the nascent scFv or the antibod). molecule outside of the ribosome tunnel. Under optimised 
conditions, these properly folded ribosome-displayed antibodies can be subjected to &nity selection. 
The nRNA in the @nity-selected ribosome-displayed scFv complex can be extracted fop. use in RT- 
PCR to generote the darble-stranded cDNA that can be subjected to another cycle of selecrion. 
1.4 Immunoassays 
Immunoassays are analytical techniques that rely on the use of antibodies specific for 
a certain compound for its detection in a complex sample or matrix. Immunoassays 
are extensively used to quantify a large range of molecules due to their accuracy and 
specificity, both of which relate to the affinity of the antibody for the target analyte. 
In addition, immunoassays are inexpensive, fast and convenient. 
Immunoassays can be divided into several categories depending upon the label used 
to detect the antibody-antigen interaction. Radioimmunoassays (RIA) use 
radioisotopes for detection, fluorescent immunoassays (FIA) involve fluorescently- 
labelled antibodies, and enzyme-labelled antibodies are involved in enzyme-linked 
immunosorbent assay (ELISA). In addition, immunoassays can be defined as fluid 
phase or solid phase depending on whether the assay is carried out in solution, i.e. 
antibody 1 antigen interaction and detection mechanism occurs in solution (Brennan et 
al., 2003) or immobilised onto the surface of plastic or other support matrices i.e. 
antibody / antigen interaction is immobilised and detection is based on presence on 
the matrix surface (Dillon et al., 2003), and whether or not a separation step is 
necessary (Gosling, 2000). 
1.4.1 Enzyme-linked immunosorbent assay @LISA) 
ELISA is a frequently used immunoassay format for the detection of a wide range of 
molecules, and its reliability is well established. It is the most common assay format 
used for initial characterisation and evaluation of antibodies destined for other 
immunoassays. The assay can be conducted using polyclonal, monoclonal or 
recombinant antibodies. In an ELISA, an enzyme that catalyses a chromogenic or 
chemiluminescent reaction is used to label an antibody or antigen. This is then used 
to detect the presence of the corresponding antibody or antigen in the sample being 
assayed. The intensity of the colour or the light produced by the enzyme upon 
addition of the substrate can be accurately measured to allow quantitative analysis 
(Liddell, 2001). The enzyme horseradish peroxidase (HRP) is often used in 
conjunction with chromogenic substrates such as diammonium-2,2'-azino-bis (3- 
ethylbenzothiazole-6-sulfonate) or o-PD (0-phenylenediamine). The end product 
I 
from this reaction is measured spectrophotometrically. These substrates are selected 
due to the fact that they are easy to prepare and are available at a reasonable price 
(Yau et al., 2003). 
A direct, non-competitive ELISA involves direct detection of the analyte present in a 
sample. Antigen is added to the wells of a solid support matrix, and upon incubation 
becomes immobilised through hydrophobic interactions. A protein solution (e.g. a 
5% (wIv) solution of milk protein) is then added and incubated in order to block any 
remaining sites on the surface of the support matrix and avoid subsequent non- 
specific interactions. Any unbound protein is then washed from the surface using 
I phosphate-buffered saline (PBS) and PBS - 0.04% (v/v) Tween (detergent). 
Antibody specific for the antigen is then added and incubated to allow binding to the 
irnmobilised antigen. The wells are again washed to remove any unbound protein. A 
secondary, enzyme-labelled antibody specific to the primary antibody is then added 
and the surface incubated. Excess antibody is then washed away. The presence of 
this secondary antibody can then be measured following the addition of a suitable 
substrate for the enzyme label. This is detected spectrophotometrically with suitable 
controls and standards for the use for the construction of a calibration curve. From 
this information, the quantity of antigen present in the sample can be measured 
(Figure 1.8). 
A competitive ELISA involved determination of analyte concentration by competition 
with a known concentration of analyte for specific binding to the antibody. In this 
case, antibody is immobilised to the surface and the remaining sites blocked with 
protein solution, as described before. The plate is washed, and a known concentration 
of enzyme-labelled antigen, plus an equal volume of the sample, containing an 
unknown quantity of the antigen, is added simultaneously to the surface and 
incubated. During incubation, both the labelled and unlabelled antigen compete for 
specific binding to the immobilised antibody. The surface is then washed to remove 
any unbound antigen, substrate is added and the absorbance read 
spectrophotometrically. Since only the labelled antigen that has been captured by the 
antibody is detected, the signal measured in inversely proportional to the quantity of 
antigen present in the original sample (Figure 1.9). 
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Figure 1.8 Schematic diagram of a typical direct ELISA. Each step requires an appropriate incubation 
period (usual& 37 '~ for  1 hour). Antigen is coated onto a well of a microtiwe plate. The remaining 
sites on the plate are blocked with aprotein solution toprevent non-spec$c binding to the plate. ScFv 
is added and binds to the immobilised antigen. Unbound scFv is washed away and a secondmy, 
enzyme-labelled anfib04 is added to the well. Thir is allowed to bind the scFv and unbound anfib04 
is washed away. Finally, substrate spec$c for the enzyme is added, and the absorbance is measured 
spec~ophotome~ical&. 
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Figure 1.9 Schematic diagram of a typical competitive ELISA. ScFv specific for the antigen are coated 
onto a well of a microtitreplate. The remaining sites on the plate are blocked toprevent non-speciJTc 
binding to the plate. Labelled antigen is added simultaneously with the sample containing the unknown 
antigen concentration. Labelled and unlabelled antigen compete for the immobilised scFv. Unbound 
antigen is washed away and substrate specz$c for the enzyme is added TEe absorbance is measured 
spectrophotometrica~. The result obtained is taken as inversely proportional to the free antibody 
presenr in the sample. 
1.4.2 Biosensors 
A Biacore biosensor was used in the research described to develop inhibitive 
immunoasssays. The Biacore works on the principle of surface plasmon resonance, as 
discussed in Section 3.1.3, and can, therefore, be used to develop immunoassays to 
various compounds. With this system, either hapten or antibody may be immobilised 
onto the surface of the chip. However, immobilisation of the hapten may prove 
difficult depending on the functional groups avaable. Therefore, some assay formats 
require the immobilisation of protein-hapten conjugates onto the surface. Standards 
containing varying concentrations of free hapten are prepared and premixed with 
antibody and, after a suitable incubation time, passed over the surface of the chip with 
protein-hapten conjugate immobilised. A proportion of the antibody has already 
bound to the free hapten, inhibiting further binding to the surface. Therefore, the 
amount of antibody that binds to the surface is inversely proportional to the amount of 
free hapten in solution (Figure 1.10). The results of this immunoassay may be used in 
the construction of a standard curve and unknown target analyte concentrations 
determined from such a curve. 
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Figure 1.10 Schematic representation of a Biacore inhibitive immunoassay format for quantatitive 
determination of a hapten. Standard o f f ee  hapten and antibody werepremixed, incubated andpassed 
over the suflace of a chig with protein-hapten conjugate immobilised on its surface. Any unbound 
antibody binds to the immobilised hapten. Antibody already bound to free hapten is subsequently 
washed away. The amount of immobilised antibody is, therefore, inversely proportional to the amount 
offree hapten in solution. 
1.5 Aims of Research 
The aim of this project was to develop antibodies to Zilpaterol for use in competitive 
ELISA immunoassays and rapid and sensitive Biacore immunoassays for the analysis 
of these compounds. The aim was also to produce a recombinant form of Prostate- 
Specific Antigen (PSA) and to develop a competitive ELISA using commercial anti- 
PSA antibodies. 
Chapter 3 describes the characterisation of anti-zilpaterol rabbit polyclonal antibodies 
and the subsequent development of a competitive ELISA immunoassay for the 
detection of free zilpaterol. Cross reactivity studies were then carried out with four P- 
agonists, and a number of other potential cross-reactants. The polyclonal antibodies 
were then used in the development of a Biacore-based inhibition immunoassay for the 
detection of free zilpaterol. The chapter also describes the development of a 
combinatorial phage display library using the system devised by Krebber et al. for the 
production of single chain Fv (scFv) antibodies that detect zilpaterol. Competitive 
ELISA and Biacore inhibition imrnunoassays were developed for the detection of 
zilpaterol using an affinity selected scFv antibody. Cross reactivity studies were also 
conducted using the same potential cross-reactants. 
Chapter 4 describes the cloning, expression and purification of a recombinant form of 
prostate-specific antigen protein, and its use in the development of a competitive 
ELISA. 
Chapter 2 
Materials and Methods 
2.1 Materials and equipment 
2.1.1 Materials 
All reagents and chemicals were supplied by Sigma-Aldrich Co. (Poole, Dorset: 
U.K.), unless listed below (Table 2.1). 
Table 2.1 
Reagent 
Acetic acid 
Hydrochloric acid 
Sodium chloride 
Tween 20 
Parathion 
Bacteriological Agar 
Yeast Extract 
PBS tablets 
Bicinchoninic acid assay (BCA) kit 
DNA ligase 
Hepes 
HPLC-gade solvents 
Hydrogen peroxide 
PCR Optimizer Kit 
~ r o ~ o n d ~ ~  Resin 
PCR Primers 
Sfil enzyme 
VCSM13 Helper Phage 
Wizard Plus Mini-prep kit and PCR 
prep DNA purification kit 
PCR-related Reverse-Transcription 
System 
Supplier 
Riedel de-Haen AG, Wunstorfer, Strabe 40, D- 
l I Oxoid, Basingstoke, Hampshire, RG24 SPW, 
England. 
I I Pierce and Waniner (UK) Ltd., Chester, England. 
Boehringer-Mannheim Ltd., East Sussex, England. 
I I BDH Chemicals Ltd., Poole, Dorset, England. 
Invitrogen, 9704-CH-Groningen, Netherlands. 
Sigma-Genosys Ltd, Cambridge CB2, England. 
New England Biolabs, Hitchin, Herts., England. 
I 1 Stratagene, North Torrey Pines Rd. La Jolla, USA. 
, 1 Promega Corporation, 2800 Wood Hollow Rd, 
Madison, WI 5371 1-5399, USA. 
2.1.2 Equipment 
Equipment 
Atto dual minislab 43-6450 
BIAcore 1 0 0 0 ' ~  
BIAcore 3 0 0 0 ~  
CM5 chips 
Eppendorf tubes 
Sterile universal containers 
Heraeus Christ Labohge 6000 
Biofuge A Microcentrifuge 
Titretek Twinreader Plus 
Image Master VDS 
IR Spectrophotometer 
NMR Spectrometer, 400MHz AC400 
NUNC Maxisorb plates 
3015 pH meter 
Orbital incubator 
RM6 Lauda waterbath 
T-Gradient BIOMETRA-PCR 
Millipore Filtration Apparatus 
SBl Blood tube rotator 
Sorvall RC-5B refrigerated centrifuge 
Sterile cell culture lab clothing 
Stuart Platform Shaker (STR6) 
Ultrafiltration cell 8400 
W-160A spectrophotometer 
W P  Imagestore 7500 gel 
documentation system 
Supplier 
Atto Corp, Bunhyo-Kui, Tokyo 113, Japan. 
Phamacia Biosensor AB, Uppsala, Sweden. 
Sarstedt, Wexford, Ireland. 
Heraeus Instruments Inc, 11 1-a Corporate 
Boelevard, South Plainfield, New Jersey, USA. 
Medical Supply Company, Damastown, 
Mulhuddart, Dublin 12, Ireland. 
Pharmacia Biotech, San Francisco, CA., USA. 
The Nicolet Instrument Corp., Madison, USA. 
Brucker, Coventry, CV4 9GH, England. 
NUNC, Kamstrup DK, Roskilde, Denmark. 
Jenway Ltd., Essex, England. 
Gallenkamp, Leicester, England. 
AGB Scientific Ltd., Dublin Industrial Estate, 
Glasnevin, Dublin 9, Ireland. 
Stuart Scientific, London, England. 
Du Pont instruments, Newtown, Connecticut, 
USA. 
Brownes, Foxrock, Dublin, Ireland. 
Lennox, Naas Rd., Dublin, Ireland. 
Amicon Inc. Beverly, Massachusetts 01915, USA. 
Shimadzu Corp., Kyoto, Japan. 
Ultra Violet Products, Upland, CA., USA. 
2.1.3 Composition of culture media 
Culture media formulations 
2 x Tryptone and yeast extract (TY) medium 
Luria broth (LB) medium 
Non-expression medium (NE)  
Low expression medium (LE) 
Expression Medium (EM) for soluble scFv 
antibodies 
Tryptone and yeast extract (TYE) medium m 
Tryptone 16 g/l 
Yeast Extract 10 gil 
NaCl 5 dl 
Tryptone 16 g/l 
Yeast Extract 10 gil 
NaCl 5 d l  
Bacteriological agar 15 g/l 
Tryptone 16 g/l 
Yeast Extract 10 g/l 
NaCl 5 d l  
Glucose 1%, vlv 
Chloramphenicol 25 pgml 
Tryptone 16 g/l 
Yeast Extract 10 g/l 
NaCl 5 d l  
Glucose 1%, v/v 
Chloramphenicol 25 pgiml 
CPTG 0.5 mM 
2 x TY medium 
~hloramphenicol 25 pdml 
rryptone 20 g/l 
Yeast Extract 5 dl 
NaCl 0.5 g/l 
KC1 2.5 mM 
MgClz 20 mM 
Glucose 20 mM 
PH 7.0 
2 x TY medium 
Bacteriological agar 15 gil 
2.1.4 Buffers 
Phosphate buffered saline (PBS) 
One tablet (Oxoid) was dissolved per 100 mls of distilled water according to 
manufacturer's instructions. When dissolved, the tablets prepare Dulbecco's A PBS 
which contains 0.15 M NaCl, 2.5 mM potassium chloride, 10 mM disodium hydrogen 
phosphate and 18 mM sodium dihydrogen phosphate, pH 7.4. This buffer will be 
referred to throughout as PBS. 
Tris buffered saline (TBS) 
Tris buffered saline containing 1 mM CaC12, 0.05 M Tris, 0.15 M NaCl, pH 7.4, was 
prepared and used as the dilution buffer for the monoclonal anti-FLAG antibody 
(FLAG is a small hydrophilic tag which improves detection and purification of 
recombinant proteins). The anti-FLAG antibody is used for western blotting and 
ELISA analysis of soluble scFv's. 
Tris-acetic acid-EDTA buffer (TAE) 
A stock solution of 50 X TAE buffer was prepared by dissolving 242 g Tris, and 
addition of 57.1 ml glacial acetic acid followed by 100 ml of 0.5 M EDTA, pH 8.0 in 
a final volume of 1 litre. All gels were run in 1 X TAE. 
Hepes Buffered Saline (HBS) 
Hepes buffered saline (BIACORE running buffer) containing 50 mM NaCl, 10 mM 
HEPES, 3.4 mM EDTA and 0.05% (v/v) Tween-20 was prepared by dissolving 8.76 g 
of NaCl, 2.56 g of NEPES, 1.27 g of EDTA and 500 p1 of Tween 20 in 800 ml of 
distilled water. The pH of the solution was then adjusted to pH 7.4, by the addition of 
2 M NaOH. The final volume was then made up to 1,000 ml in a volumetric flask. 
The solution was filtered through a 0.2 pm filter (Sartorius) and degassed prior to use. 
1 
2 3  Characterisation of polyclonal antibodies 
2.2.1 Licensing for drug use 
The possession and use of zilpaterol for analytical purposes was licensed by the 
Department of Health. 
2.2.2 Production of zilpaterol-specifie polyclonal antibodies 
Immunisation of New Zealand White female rabbits with covalently-linked zilpaterol- 
I HSA conjugate and isolation of serum containing the zilpaterol-specific polyclonal 
antibodies was conducted by the Department of Agriculture and Rural Development 
for Northern Ireland, Queens University, Belfast. This antibody was designated as 
R699. 
2.2.3 Competitive checkerboard ELISA to determine optimal zilpaterol and 
R699 potycIonal antibody concentrations 
An ELISA plate (Nunc) was coated with varying dilutions of R699 polyclonal 
antibody (1/1600 to 1125600) in 10 mM sodium acetate buffer, pH 7.2, with 100 yl of 
each dilution added to a different row on the ELISA plate and incubated for 1 hour at 
37'~. The plate was blocked with PBS containing 5% (wlv) milk marvel, incubated 
at 3 7 ' ~  for 1 hour and then washed 3 times with PBS. A 114000 dilution (final 
dilution) of HRP-labelled zilpaterol was mixed with varying concentrations of free 
zilpaterol0.48 to 500 nglml (final concentrations) and 100 pl of each was added to a 
different column on the ELISA plate. The plate was then incubated for 1 hour at 3 7 ' ~  
and washed 3 times with PBS containing 0.05% (vlv) tween (PBST) and 3 times with 
PBS. 100 pl OPD substrate (0.4 mglml o-phenylenediamine in 0.05 M phosphate 
citrate buffer, pH 5.0) was added per well and the plate was incubated for 30 minutes 
at 37 '~ .  Absorbance readings were taken at 450 nm. 
2.2.4 Buffer optimisation for R699 polyclonal antibody ELISA 
The ELISA was conducted using several different buffers in order to determine the 
optimal buffer for this assay. 
2.2.4.1 Competitive ELISA to determine optimal R699 polyclonal antibody 
coating buffer 
An ELISA plate (Nunc) was coated with a 111600 dilution of polyclonal antibody 
diluted in 4 different buffers; lOmM sodium acetate buffer, pH 7.2, PBS, pH 7.4, 
0.05M carbonate buffer, pH 9.6 and 25mM TBS, pH 7.4. The plate was blocked with 
PBS containing 5% (wlv) milk marvel, incubated at 3 7 ' ~  for 1 hour and then washed 
3 times with PBS. 50 p1 zilpaterol-HRP, to a final dilution of 114000, were added to 
each well of the plate, followed by 50 pl of free zilpaterol with concentrations ranging 
from 0.06 to 1000 ng/ml. The assay was completed as described in Section 2.2.3. 
2.2.4.2 Competitive ELISA to determine optimal zilpaterol dilution buffer 
An ELISA plate (Nunc) was coated with a 111600 dilution of polyclonal antibody 
diluted in lOmM sodium acetate buffer, pH 7.2, and incubated for 1 hour at 37 '~ .  
The plate was blocked with PBS containing 5% (wlv) milk marvel, incubated at 3 7 ' ~  
for 1 hour and then washed 3 times with PBS. Zilpaterol-HRP, to a final dilution of 
114000, and free zilpaterol, with dilutions ranging from 1000 ng/ml to 0.06 ng/ml 
(final dilutions), were added to the plate. The dilutions were made up in 4 different 
buffers; 10 mM sodium acetate buffer, pH 7.2, PBS, pH 7.4, 0.05M carbonate buffer, 
pH 9.6 and 25mM TBS, pH 7.4. The assay was completed as described in Section 
2.2.3. 
2.2.5 Competitive ELISA with R699 polyclonal antibody 
An ELISA plate-(Nunc) was coated with a 111600 dilution of polyclonal antibody in 
10 mM sodium acetate buffer, pH 7.2, and incubated for 1 hour at 37'~. The plate 
was blocked with PBS containing 5% (wlv) milk marvel, incubated at 3 7 ' ~  for 1 hour 
and then washed 3 times with PBS. Zilpaterol-HRP, to a fmal dilution of 1/4000, and 
free zilpaterol, with concentrations ranging from 0.06 to 1000 nglml were added to 
the plate. All dilutions were made in 10 mM sodium acetate buffer, pH 7.2. The 
assay was described in Section 2.2.3. 
2.3 Production of a murine scFv antibody library to zilpaterol 
2.3.1 Immunisation and total RNA extraction 
Immunisation of BALBIc mice with zilpaterol-HSA conjugate and total RNA 
extraction from the spleen was conducted by Dr. Paul Dillon, Dublin City University. 
2.3.2 Reverse transcription of mouse spleen mRNA 
Complementary DNA (cDNA) was synthesised from the total RNA using a Promega 
cDNA synthesis kit containing random hexamer primers. 4 p1 of mRNA was used per 
20 p1 total reaction volume, into which was also added MgC12, 2 p1 5x buffer, 2 pl 
dNTPs, 0.5 pl random primers, and brought to a final volume of 20 pl with RNAse 
free HzO. The reaction was mixed and left at room temperature for 10 minutes to 
- 
allow primer annealing, then incubated at 42OC for 1 hour to allow for cDNA 
synthesis. The presence of cDNA was then observed by gel electrophoresis. 
2.3.3 Amplitication of antibody light and heavy chain genes 
2.3.3.1 PCR primers 
The listed PCR primers were obtained from Sigma-Genosys Ltd and designed to be 
compatible with the pAK vector system as described by Krebber et al. (1997). 
Variable light chain back primers 
LB 1 5'gccatggcggactacaaauATCCAGCTGACTCAGCC3' 
LB2 5'gccatggcggactacaaaGAyATTGTTCTCwCCCAGTC3' 
LB3 5'gccatggcggactacaaaGAyATTGTGMTTMACTCAGTC3' 
LB4 5'gccatggcggactacaaaGAyATTGTGYTRACACAGTC3' 
LB5 5'gccatggcggactacaaaGAyATTGTMTGAChJCAGTC3' 
LB6 5'gccatggcggactacaaaQ4JATT&4GATTRAMCCAGTC3' 
LB7 5'gccatggcggactacaaaGAyATTCAGATGA~CAGTC3' 
LB8 5'gccatggcggactacaaaGAyATyCAGATGACACAGAC3' 
LB9 5'gccatggcggactacaaa~ATTGTTCTCAwCCAGTC3' 
LBlO 5'gccatggcggactacaaaGAyATTG&GCTSACCCAATC3' 
LBl 1 5'gccatggcggactacaaaGAyATTSTuTGACCC~C3' 
LBl2 5'gccatggcggactacaaaGAyRTT~TGATGACCCA&4C3' 
LB 13 5'gccatggcggactacaaa~YATTGTGATGACIJCAGKC3' 
LB14 5'gccatggcggactacaaaGAyATTGTGATAAC~CAGGA3' 
LB 15 5'gccatggcggactacaaacAyATTGTGATGACCCAG~T3' 
LB 16 5'gccatggcggactacaaa@iJATTGTGATGACACAACC3' 
LB17 5'gccatggcggactacaaaGAyATTTTGCTGACTCAGTC3' 
LBL 5'gccatggcggactacaaa~YGCTGTTGTGACTCAGGAATC3' 
Variable light chain forward primers 
LF1 5'ggagccgccgccgcc(agaaccaccaccacc)~ACGTTTGATTTCCAGC~GG3' 
LF2 5'ggagccgccgccgcc(agaaccaccaccacc)~ACGTTTATTTCCAGCTTGG3' 
LF3 5'ggagccgccgccgcc(agaaccaccaccacc)~ACGTTTTATTTCCAACTTTG3' 
LF4 5'ggagccgccgccgcc(agaaccaccaccacc)~ACGTTTTATTTCC~CTTTG3' 
LF5 5'ggagccgccgccgcc(agaaccaccaccacc)~ACGTTTCAGCTCCAGCTTGG3' 
LFh 5'ggagccgccgccgcc(agaaccaccaccacc)~ACCTAGGACAGTCAGTTTGG3' 
Variable heaw chain back primers 
HB1 5'ggcggcggcggctccggtggtggt~GAK_GTAK_RMAGCTTCAGGAGTTC3' 
HB2 5'ggcggcggcggctccggtggtggtmGAGGTEJCAGCTIJCAGCAGTC3' 
HB3 5'ggcggcggcggctccggtggtggt~CAGGTGCAGCTGAAG~ASTC3' 
HB4 S'ggcggcggcggctccggtggtggt~GAGGTCC&CTGCAAC&TC3' 
Variable heavy chain f o m d  primers 
HFl ~ '~~~~~~cBccc~~&GAGGAAACGGTGACCGTGGT~ '  
HF2 5'ggaattcmcccgagg&GAGGAGACTGTGAGAGTGGT3' 
HF3 ~'~~~~~~cBccc~~&GCAGAGACAGTGACCAGAGT~' 
HF4 5'ggaattcmcccgagg&GAGGAGACGGTGACTGAGGT3' 
2.3.3.2 PCR amplification of light and heavy chain genes 
Component 
cDNA 
dNTP 
5 X buffer 
Forward primers 
Reverse primers 
Ultrapure water 
Tag polymerase (SU/pl)* 
Volume added 
2 1rl 
1 PI 
10 pl 
1 PI 
1 PI 
35 pl 
5 PI 
2.3.3.3 PCR conditions for amplification of light and heavy chain genes 
Typical thermal cycling conditions were as follows: 
95°C X 5 min 'Hot Start' 
* Tag polymerase added to the reaction mix at this point 
94°C X 1 rnin 
63°C X 30 sec 
58°C X 50 sec 
72°C X 1 min 
repeat X 7 cycles 
94OC X 1 min 
63OC X 30 secs 
72OC X 1 min 
repeat X 24 cycles 
All ramping rates were at 4°~/sec 
2.3.3.4 Purification of PCR reaction products 
PCR purification was performed using the Wizard PCR prep DNA purification kit 
(Promega). An Atto AE-6100 gel electrophoresis system was used. The PCR product 
was run on a 1% (wlv) low melt agarose gel containing 0.5 pg/ml ethidium bromide. 
The 400bp fkagment was cut kom the gel with a sterile scalpel and the DNA purified 
from the low melt agarose as follows. The excised band was placed into an eppendorf 
tube and weighed. Three volumes of buffer were added for every one volume of the 
gel fragment, and the eppendorf tube was incubated in a water bath at 50°C for 5 to 10 
minutes until the agarose had melted. One volume of isopropanol equal to the 
original gel slice volume was added and the solution was mixed. The solution was 
added to a spin column and placed into a 2 ml collection tube. The column was then 
centrifuged at room temperature for 1 minute at 14,000 rpm, and the filtrate discarded. 
750 pl of wash buffer was added and the column centrifuged as before. The filtrate 
was discarded and the column added to a new 2 ml collection tube. 30 pl of ultra pure 
Hz0 was added and the column centrifuged as before. The eluted DNA fiagment was 
stored at - 20°C until required. 
2.3.3.5 Quantification of purified PCR products 
After purification the fragments were re-electrophoresed on an agarose gel with a 
quantatitive Molecular Weight Marker (Promega, 100 bp (100 - 4,000 range) 
Molecular Weight Markers), as the concentration must be determined prior to splice 
by overlap extention PCR (SOE-PCR). The 500 bp fiagment of this marker was used 
as a reference for densiometric quantitation as 5 pl contains 150ng of the 500 bp 
fkagment and 50ng of the other molecular weight fragments. 
2.3.4 Components of splice by overlap extention (SOE) PCR 
The purified light and heavy chain genes (approximately 400 bp each) were joined 
and amplified together to produce an 800 bp fiagment by SOE-PCR. 
SOE Primers 
Single chain back 5'ttactcgc~cagccpgccatggcg~actaccccg3' 
Single chain forward 5'ggaattcggcccccgag3' 
The components for amplification of joined antibody light and heavy chain genes by 
SOE-PCR are as follows: 
Component Stock concentration 
10 X Buffer 10 X 
dNTPs 2OmM 
VH as determined 
Working concentration 
1 X 
0.4 mM 
10 ngtreaction 
VL as determined 10 nglreaction 
scfor varied 0.05 nmol/reaction 
scback varied 0.05 nmollreaction 
up&o to 50 pl including Taq, 
DNA and scfor, scback 
Tag polymerase 5 Ulpl 5 Ulreaction 
2.3.4.1 SOE-PCR conditions for amplification of joined antibody light and heavy 
chain genes 
94°C X 1 min 
45OC X 5 min 
72'C X 1 min 
repeat X 5 cycles 
*0.05 mM scfor and scback primers and 5U Tag polymerase added per reaction at Chis 
point 
94°C for 1 min 
63OC X 30 sec 
72°C X 1 min 
repeat X 25 cycles 
All ramping rates were at 4'~/sec 
2.3.5 Preparation and purification of pAKlOO vector using Wizard miniprep 
system (Promega) 
A single colony of E. coli XL1-Blue containing pAKlOO (all vectors were kindly 
donated by Andreas Pluckthun, University of Zurich, Switzerland) was picked off an 
agarose plate and grown overnight at 37OC with vigorous shaking in 5 ml 2 x TY 
supplemented with 30 pgtml tetracycline. Purification of the plasmid was carried out 
using the Wizard miniprep system as follows: 
The 5 ml culture was centrifuged for 5 minutes at 4000 rpm, the supernatant decanted 
and the tubes blotted dry on a paper towel. 250 p1 of cell resuspension solution (50 
mM Tris-HC1, pH 7.5,10 mM EDTA and 10 yg/ml RNase A) was added and the cell 
pellet completely resuspended by vortexing or pipetting. The mixture was transferred 
to a sterile 1.5 ml microcentrifuge tube, 250 pl of cell lysis solution (0.2 M NaOH and 
1% (wlv) SDS) added and mixed by inverting the tube 4 times. The suspension was 
incubated for 1-5 minutes before 10 p1 of alkaline protease solution was then added 
and mixed by inverting the tube 4 times (alkaline protease inactivates endonucleases 
and other proteins released during the lysis of the bacterial cells that can adversely 
affect the quality of the isolated DNA). After 5 minutes incubation at room 
temperature, 350 p1 of Wizard plus SV neutralisation solution (pH 4.2 buffer 
containing 4.09 M guanidine hydrochloride, 0.759 M potassium acetate and 2.12 M 
glacial acetic acid) was added and immediately mixed by inverting the tube 4 times. 
The bacterial lysate was then centrifuged at 14000 rpm for 10 minutes at room 
temperature. The cleared lysate was transferred (approx. 850 pl) to the prepared spin 
column by decanting. The supernatant was again centrifuged at 14000 rprn for 1 
minute at room temperature, the spin column removed from the tube and the flow 
through discarded. 750 p1 of column wash solution (162.8 mM potassium acetate, 
22.6 mM Tris-HC1, pH 7.5 and 0.109 mM EDTA), previously diluted with 95% (vlv) 
ethanol, was then added to the spin column. The supernatant centrifuged at 14000 
rpm for 1 minute at room temperature and the flow through again discarded from the 
collection tube. The wash procedure was repeated using 250 yl of column wash 
solution. The supernatant was centrifuged at 14000 rpm for 2 minutes at room 
temperature, and the spin column subsequently transferred to a new sterile 1.5 ml 
microcentrifuge. The plasmid DNA was finally eluted by addition of 100 p1 of sterile 
ultra pure water to the spin column and centrifuging the supernatant at 14000 rpm for 
1 minute at room temperature. After eluting the plasmid DNA, the spin column was 
discarded and DNA stored in the microcentrifuge tube at -20°C. 
2.3.6 Digestion of pAKlOO and antibody light and heavy chain genes SOE-PCR 
products 
Digestion of pAKlO0 and SOE-PCR products were performed using the Sfil 
restriction enzyme. pAKlOO requires digestion with Sfil restriction enzyme prior to 
ligation with light and heavy chain genes. Antibody light and heavy chain gene SOE- 
PCR products are also digested with S'l in order to facilitate ligation. 
Components 
5 p1 reaction buffer (10X) 
0.5 pl BSA 
0.5 p1 S$ I (10 U) 
150-250 nglreaction SOE-PCR product or 250-500 nglreaction pAKlOO vector 
Sterile ultrapure water was added to a final volume of 50 pl. 
The mixture was incubated at 50°C overnight. The fragments were purif~ed using a 
Promega purification kit, as described previously in Section 2.2.3.4. 
2.3.7 Ligation of antibody light and heavy chain genes into the pAK 100 vector 
Purified SOE-PCR products were ligated into the pAKlOO plasmid vector at a ratio of 
1.5: 1. The reaction was carried out under the following conditions: 
Com~onents 
300 ng pAKl00 vector 
200 ng purified SOE light and heavy chain genes 
4 pl ligase (4 U) 
5 pl reaction buffer (10 X) 
Sterile ultrapure water was added to give a final volume of 50 pl 
The reaction mixture was incubated at 16'C overnight and transformed into E. coli 
XL1-blue competent cells. 
2.3.8 Preparation of high efficiency competent cells 
High efficiency competent cells were prepared as previously described by Inoue et al. 
(1990). A stock of E. coli XL1-Blue was streaked on 2xTY agar containing 25 pg/ml 
chloramphenicol and incubated at 3 7 ' ~  overnight. Approximately 10-12 large 
colonies were removed from the plate and inoculated into 250 ml of SOB medium 
containing 25 pl/ml chloramphenicol in a 2 litre baffled flask. The culture was grown 
at lS°C with vigorous shaking (200-250 rpm) until an OD600 of 0.6 is reached. The 
culture was then placed on ice for 10 minutes before being transferred to two 250 ml 
centrifuge tubes and spun at 4000 rpm at 4OC for 5 minutes in a Beckman J2-21 
centrifuge. The pellets were resuspended in 40 ml of ice-wld TB buffer (10 mM 
pipes, 15 rnM CaC12, 150 mM KCl, pH adjusted to 6.7 with KOH and 55mM MnC12, 
sterile filtered and stored at 4'C), placed on ice for 15 minutes, pooled and centrifuged 
as before. The cell pellet was resuspended in 20 ml of ice-cold TB buffer and DMSO 
added slowly with gentle swirling to a final concentration of 7% (vlv). After 
incubation in an ice bath for 10 minutes the cell suspension was dispensed in 0.4 ml 
aliquots into microcentrifuge tubes. The cells were immediately flash frozen in liquid 
nitrogen and stored at -80°C. 
2.3.9 Transformation of E. coli m1-Blue competent cells with pAK 100 vector 
containing light and heavy chain genes and measurement of transformation 
efficiencies 
Competent E. coli XL1-Blue (Stratagene) cells were thawed gently on ice. The cells 
were gently mixed by hand and 200 p1 transferred into two 20 ml sterilin tubes (one 
tube for the experimental transformation and the other tube for the control 
transformation). 0.1-50 ng of vector, containing light and heavy chain genes was 
added to one of the tubes and swirled gently. 1 11 of pUC18 control vector was added 
to the second tube and also swirled in the same manner. Both tubes were then 
incubated on ice for 30 minutes. The cells were then heat pulsed for 30 seconds at 
4 2 ' ~  followed by incubation on ice for 2 minutes. 0.8 ml of SOC medium, 
preincubated at 37OC, was then added and the tubes incubated at 37°C for 1 hour with 
shaking at 225-250 rpm. 100 p1 of the resulting pAKlOO tramformants were plated 
out onto LB media supplemented with 25 pglml chloramphenicol and 1% (w/v) 
glucose. The control transformants were plated out on LB agar supplemented with 25 
pllml ampicillin. Both sets of plates were allowed to grow overnight at 37OC. 
pAK100 transformed colonies were scraped off the plates and used as library stocks. 
These stocks were suspended in 15% (vlv) glycerol and stored at -80°C. 
2.4 Production of scFv antibodies to zilpaterol 
2.4.1 Rescue of scFv displaying phage 
50 ml of non-expression (NE) media (2 x TY containing 1% (wlv) glucose and 25 
pllml chloramphenicol) was inoculated with 100 p1 cells from the stock antibody 
library. The culture was grown with shaking at 37OC until the O.D.550 = 0.5, then 
incubated for 10 minutes at 3 7 ' ~  without shaking. 10" cfu of helper phage 
(VCSM13) and 25 pl of 1M IPTG solutions were added to the culture, followed by 
incubation for 15 minutes at 37OC without shaking. The culture was then diluted in 
100 ml low expression (LE) medium WE medium containing 0.5 mM IPTG) and 
shaken for 2 hours at 26OC to allow phage production. 30 pg/ml kanamycin was 
added to the culture and it was incubated as before for a further 8 hours. A phage 
particle precipitation was then done using PEGiNaCl to purify and concentrate the 
phage. 
2.4.2 PEGNaCl precipitation 
150 ml of the E. coli XL1-bluellibrary was transferred to a sterile Sorvall 250 ml 
centrifuge tube and spun at 10,000 rpm for 10 minutes at 4OC. The supematent was 
collected and 20% of the volume of PEGiNaCl(36.525g NaCl and 50g PEG 10,000 in 
250 ml H20) was added, mixed and incubated on ice for 1 hour. The mixture was 
then centrifuged at 10,000 rpm for 20 minutes at 4OC. The supematent was removed 
and the pellet was centrifuged again at 7000 rpm for a further 10 minutes at 4'C. Any 
remaining supematent was removed. The pellet was then resuspended in 2 ml sterile 
filtered PBS, then micro-centrifuged at 4000 rpm for 10 minutes at 4OC to remove any 
bacterial debris. The phage-containing supernatant was retained and stored at 4OC for 
the short term, or at -80°C in a 15% (vlv) glycerol solution. 
2.4.3 Phage titre 
5 ml of 2 x TY containing 30 pg/ml tetracycline was inoculated with a single colony 
of XL1-blue and grown overnight at 37°C. The culture was then diluted 11100 in 5 ml 
of 2 x TY containing 30 pg/d tetracycline and left to grow shaking at 37OC until 
O.D.550 = 0.5-0.6. It was allowed to stand at 37°C for 15 minutes without shaking. 
Serial dilutions (10.' - lo-") of phage were prepared using the bacterial culture (180 
pl E. coli XL1-blue + 20 pl phage) and incubated for 30 minutes at 37OC without 
shaking. I00 pl of each dilution was spread on 2 x TY agar plates containing 25 
pg/ml chloramphenicol and 1% (vlv) glucose. Colonies were allowed to grow 
overnight at 37OC. 
2.4.4 Aff~nity selection of antigen binders by biopanning 
A NUNC immunotube was coated with 10 pdml of zilpaterol-HSA conjugate. The 
tube was washed 5 times with PBS containing 0.05% (vlv) tween (PBST) followed by 
5 washes with PBS. The surface was then blocked with 5% (wlv) milk marvel in PBS 
and incubated for 1 hour at 37OC. The tube was washed again as above and 1 ml of 
pbagemid (10" phagelml) particles was added to 3 rnl of PBS containing 2% (wlv) 
milk marvel. This was incubated with gentle shaking for 2 hours at room 
temperature. The tube was then washed as before. The bound phage were eluted 
from the tube by adding 1 ml of 1 rnM triethylamine to the tube. The tube was mixed 
on a rotating wheel for 8-10 minutes, then neutralised using 500 p1 of 1 M Tris-HC1, 
pH 7.4. A phage titre was then carried out, as described in Section 2.3.3, to determine 
the amount of phage recovered from the panning step. 
2.4.5 Reinfection of phage displaying sc f i  antibodies 
5 ml of 2xTY containing 30 pg/ml tetracycline was inoculated with 50 p1 XL1-blue 
stock and grown with shaking overnight at 37OC. The culture was then diluted 11100 
in 5 ml2xTY containing 30 pglml tetracycline and grown shaking until the O.D.550 = 
0.4-0.5. It was then placed at 37OC without shaking for 10 minutes. 750 p1 of phage 
rescued from the panning step was added and the culture was allowed to stand at 37OC 
for 30 minutes. It was then shaken at 37OC for 1 hour before being spread on 2xTY 
agar plates containing 25 pglml chloramphenicol and colonies allowed to grow 
overnight at 37OC. 
2.4.6 Preparation of clones for phage ELISA 
Single colonies were selected from plates and used to inoculate individual wells of a 
96 well cell culture plate, each containing 200 p12xTY containing 1% (vlv) glucose, 
25 pdml chloramphenicol and 30 pglml tetracycline. Two wells were left 
uninoculated as controls. The plate was shaken at 150 rpm overnight at 37OC to allow 
growth of the colonies. This master plate was used to inoculate an identical plate, 
before addition of 15% (vlv) glycerol to each well and storage of the plate at -80°C. 
The second plate consisted of 180 pVwell 2xTY containing 1% (vlv) glucose, 25 
pglml chloramphenicol and 30 pglml tetracycline. 20 pl from each well on the 
master plate was transferred to the corresponding well on the second plate, and 
incubated shaking at 37OC for approximately 6-8 hours. 25 pl of 2xTY containing 1% 
(v/v) glucose, 25 pglml chloramphenicol, 1.5 mM IPTG and 5 x lo9 phagelml were 
added to each well after 5 hours. The culture was then allowed to stand for 30 
minutes at 37OC followed by shaking at 26OC at 150 rpm for 2 hours. The plate was 
then centrifuged at 4000 rpm for 10 minutes. The supernatant was removed and the 
pellets were resuspended in 200 pl 2xTY containing 1% (vlv) glucose, 25 p g l d  
chloramphenicol, 1.5 mM IPTG and 30 pglml kanamycin. The plate was incubated 
overnight at 26OC with shaking at 150 rpm, then centrifuged at 4000 rpm for 10 
minutes. 75 p1 of the supernatant were used for analysis of the phage by ELISA. 
2.4.7 ELISA of phage-displayed scFv antibodies 
An ELISA plate was coated with 5 pg/ml zilpaterol-HSA conjugate and incubated 
overnight at 4 ' ~ .  The plate was then blocked with PBS containing 5% (wlv) milk 
marvel for 1 hour at 37'C, then washed 3 times with PBS. 75 pl of supernatant from 
the culture plate was added to the corresponding wells on the ELISA plate. 25 pl of 
4% (w/v) milk marvel-PBS was also added into each well and mixed gently. The 
plate was left for 2 hours at room temperature, then washed 3 times with PBST and 3 
times with PBS. 100 p1 of a 111000 dilution of an anti-M13 bacterophage rabbit 
antibody was added to each well and the plate was incubated for 1 hour at 37'C, then 
washed as before. 100 p1 of a 112000 dilution of HRP-labelled anti-rabbit antibody 
per well was added and incubated and washed as before. 100 pl OPD substrate (0.4 
mglml o-phenylenediamine in 0.05 M phosphate citrate buffer, pH 5.0) was added per 
well and the plate was incubated for 30 minutes at 37OC. Absorbance readings were 
taken at 450 nm. 
2.4.8 Preparation of bacterial glycerol stocks 
Bacteria cells were inoculated into 2xTY media containing chloramphenicol and 
grown at 37°C until the 0.D.600 was 0.5-0.8. The cultures were then centrifuged at 
4000 rpm for 10 minutes and the pellet resuspended in 2xTY with 20% (v/v) sterile 
glycerol to 1/5 the original volume. Celllglycerol cultures were aliquoted into 0.5 ml 
aliquts in 1.5 ml sterile microcentrifuge tubes and flash frozen with liquid nitrogen. 
Cell stocks were stored at -80°C. 
2.4.9 Isolation of the s c f i  gene from the pAKlOO vector within the positive 
clones 
10 pl of cells from each positive clone identified was taken from the master plate and 
used to inoculate 10 ml NE medium. This was grown overnight at 37 '~ .  A plasmid 
prep was then prepared on the culture using the Wizard miniprep system as described 
in Section 2.3.5 to isolate the pAKlOO vector containing the scFv gene. The purified 
pAK100 vector was digested with the S'I digestion enzyme, as described in Section 
2.3.6, and the product was run on a 0.5% (w/v) low-melt agarose gel containing 0.5 
pdml ethidium bromide, for 2 hours at 50 V until the 800 bp fragment containing the 
light and heavy chain genes has separated from the digested pAK100 vector. The 800 
bp fragment was cut from the gel with a sterile scalpel and the DNA purified from the 
gel as described in Section 2.3.3.4. The fragment was then ready for ligation into the 
pAK400 vector. 
2.4.10 Ligation of scFv gene into pAK400 for soluble scFv antibody expression 
Ligation of the scFv gene into pAK400 was performed using the same protocol as 
described in Section 2.3.7 for ligation into pAK100. 
2.4.11 Preparation of competent E. coli JM83 bacterial cells 
Preparation of competent E. coli JM83 cells was performed using the same protocol 
as described in Section 2.3.8 for the preparation of XI,-1 Blue competent cells. 25 
pdml streptomycin-sulphate was the required antibiotic in this case. 
2.4.12 Transformation of E. coli AM83 competent cells with pAK400 vector 
E. coli JM83 competent cells were transformed with the pAK400 vector containing 
the scFv gene insert. The transformation was carried out as described in Section 
2.3.9. 
2.4.13 Soluble expression of scFv antibodies from JM83 cells containing the 
pAK400 vector with scFv gene insert 
The transformed E. coli JM83 cells were grown in 2xTY media containing 25 pglml 
chloramphenicol with shaking at 37'C until an 0.D.600 = 0.5-0.8 was reached. 
Soluble scFv production was induced by addition of 1 mM IPTG and the culture was 
incubated with shaking for a further 4-5 hours at 25OC. The culture was then 
centrifuged at 4000 rpm for 15 minutes and the supernatant stored for analysis. The 
cell pellets were resuspended in 1/10 the original volume of PBS and sonicated for 30 
seconds11 ml aliquot or 3 minutes/lO ml aliquot at an amplitude of 40 using a 
microtip Vibra cellm sonicator. The cell debris was removed by centrifugation at 
room temperature, at 14000 rpm for 5 minutes. This supernatant was also retained for 
analysis. 
2.4.14 Non-competitive ELISA for the determination of soluble scFv 
A 96 well ELISA plate (Nunc) was coated with 5 pglml of zilpaterol-HSA conjugate 
and incubated for 1 hour at 3 7 ' ~  or overnight at 4'C. The plate was then blocked 
with 200 p1 of PBS containing 5% (wlv) milk marvel and incubated at 37OC for 1 
hour. The plate was washed 3 times with PBS. Dilutions of the supernatant 
containing the scFv antibody were prepared and 100 p1 of each dilution were added to 
the wells of the plate in triplicate. The plate was again incubated at 37OC for 1 hour 
and washed with 3 times with PBS and 3 times with PBST. 100 p1 of a 11400 dilution 
of anti-flag antibody in PBS was added to each well, and the plate incubated and 
washed as before. 100 p1 of a 1i2000 dilution of an HRP-labelled anti-mouse 
antibody in PBS was then added to each well and the plate incubated and washed as 
before. 100 p1 of OPD substrate was then added to each well, and the absorbance was 
read at 450 nm afier 30 minutes using a Titretek Plate Reader Plus. 
2.4.15 Checkerboard ELISA for determination of the optimal concentrations of 
immobilised zilpaterol-HSA conjugate and scFv antibody dilution for generation 
of a competitive ELISA 
A 96-well ELISA plate (Nunc) was coated with varying zilpaterol-HSA conjugate 
concentrations (5 pg/ml, 2.5 pglml, 1.25 pglml), with 100 p1 of each concentration 
added to a different row on the ELISA plate and incubated for 1 hour at 37'C. The 
plate was then washed 3 times with PBS. The plate was blocked with PBS containing 
5% (wiv) milk marvel, incubated at 37OC for 1 hour and washed 3 times with PBS. 
Serial dilutions of the supernatant containing the scFv antibody were prepared in PBS 
and 100 pl of each dilution were added to a different column on the ELISA plate. 
The plate was again incubated at 37'C for 1 hour and washed with 3 times with PBST 
and 3 times with PBS. 100 p1 of a 1L400 dilution of anti-FLAG antibody in PBS was 
added to each well, and the plate incubated and washed as before. 100 pl of a 1/2000 
dilution of an HRP-labelled anti-mouse antibody in PBS was then added to each well 
and the plate incubated and washed as before. 100 pl of OPD substrate was then 
added to each well, and the absorbance was read at 450 nm after 30 minutes using a 
Titretek Plate Reader Plus. 
2.4.16 Competitive ELISA for soluble sc& antibody characterisation 
A 96-well ELISA plate (Nunc) was coated with the optimal concentration of the 
zilpaterol-HSA conjugate, and incubated for I hour at 37°C. The plate was blocked 
with PBS containing 5% (wlv) milk marvel, incubated at 37OC for 1 hour and washed 
3 times with PBS and 3 times with PBST. The optimised dilution of scFv-containing 
supernatant was mixed with varying concentrations of free zilpaterol(10 pglml to 4.9 
ngfml, final concentrations) and incubated at 37OC for 30 minutes. 100 p1 of each 
dilution was added to the ELISA plate in duplicate. The plate was then incubated for 
1 hour at 37OC and the assay completed as described in Section 2.4.13. 
2.5 Cloning of the gene sequences encoding PSA into E. coli 
2.5.1 Preparation of PSA gene 
The gene encoding the PSA protein was donated by Dr. Evaggelia Emmanouilidou 
from the Laboratory of Analytical Chemistry, Department of Chemistry, University of 
Athens, Greece (Emmanouilidou et al., 2002). The gene insert was provided as an 
insert in the psa.pcDNA3 vector. 
2.5.2 Transformation of psa.pcDNA3 vector into E. coliJM83 cells 
E. coli JM83-competent cells were transformed with the psa.pcDNA3 vector. The 
transformation was carried out as described in Section 2.3.9. 
2.5.3 Isolation of PSA gene 
Single colonies were selected fiom the transformation plates and used to inoculate 10 
ml NE medium. These were grown overnight at 37'C. A plasmid prep was then 
prepared on the culture using the Wizard miniprep system (as described in Section 
2.3.5) to isolate sufficient quantities of the psa.pcDNA3 vector containing the PSA 
gene. The purified psa.pcDNA3 vector could then be used as the template fi-om 
which the PSA gene was amplified. 
2.5.4 PCR amplification of PSA gene 
Comaonent 
Purified psa.pcDNA3 vector 
dNTP (1 0 mM) 
10 X buffer 
Fonvard primers (100pmol/pl) 
Reverse primers (1 00pmoYpl) 
Ultrapure water 
Taq polymerase (5Ul pl) 
Volume added 
21.11 
4 ~1 
10 pl 
1 r-l1 
1 ~1 
77 pl 
5 1.11 
The PCR conditions for amplification of the PSA gene were as follows: 
Stage I :  95°C for 10 minutes 
Stage 2: 95OC for 1 minute 
50°C for 30 seconds 
72OC for 1 minute 
(Stage 2 was repeated for 30 cycles) 
Stage 3: 72OC for 10 minutes 
2.5.5 Purification of PCR reaction products 
PCR purification was performed using the Wizard PCR prep DNA purification kit 
(Promega) as described in Section 2.3.3.4 
2.5.6 Quantification of purified PCR products 
After purification the fragment was re-electrophoresed on an agarose gel with a 
quantitative Molecular Weight Marker (Promega, 100 bp Molecular Weight Markers), 
as the concentration must be determined prior to ligation. The 500 bp fragment of this 
marker was used as a reference for densiometric quantitation as 5 p1 contains 150ng 
of the 500 bp fragment and 50ng of the other molecular weight fragments. 
2.6 Inhibition ELISA for the detection of recombinant PSA 
All the wells of a microtitre plate were coated with 100 p1 neat recombinant PSA and 
the plate was then incubated at 37OC for 1 hour. The plate was washed 3 times with 
PBS and blocked with 200 pl of 5% milk marvel for 1 hour at 37OC. The plate was 
then washed 3 times with PBS. Doubling dilutions of the recombinant PSA (i.e. 112, 
114, 116 etc) were made in PBS and pre-incubated with a fixed concentration of 
commercial rabbit-anti-PSA polyclonal antibody (at a final dilution of 1f4000). 
Samples were incubated at room temperature for 30 minutes. 100 pl of each sample 
were added to the wells of the plate in triplicate. To the last three wells, a 114000 
dilution of antibody alone was added. The plate was incubated at 37OC for 1 hour, 
washed 3 times with PBS-tween and 3 times with PBS. 100 yl of a 112000 dilution of 
anti-rabbit AP-labelled antibody was added to each well, was incubated and washed 
as before. 100 yl of pNPP substrate was added to each well. Readings were taken at 
405 nrn after 30 minutes. 
2.7 Development of SPR-based immunoassay using a Biacore 3000 instrument 
Analysis was carried out on Biacore 3000 instrument using CM5 research grade 
sensor chips. The running buffer for all Biacore experiments was HBS buffer, pH 7.4, 
containing 10 mM HEPES, 150 rnM NaC1, 3.4 M EDTA and 0.05% (vlv) Tween 20. 
The running buffer was filtered (pore size of 0.22 pn) and degassed, using a 
Millipore filtration apparatus (Millipore sintered glass filtration unit), immediately 
before use. 
2.7.1 Preconcentration studies 
Immobilisation of proteins on the gold surface was achieved by means of N- 
hydroxysuccinimide esterification. Primary amine groups present allow covalent 
attachment of biomolecules. It is necessary to carry out an initial "preconcentration" 
step, resulting from electrostatic binding of protonated amine groups on the biological 
component to negatively charged carboxyl groups on the chip surface to take place. 
Preconcentration of a desired protein on the sensor surface can be facilitated by 
adjusting the pH below the isoelectric point ($1) of the protein. Therefore, protein 
solutions were prepared in 10 mM sodium acetate at a range of different pHs and 
these solutions passed over an underivatised chip surface, with the degree of 
electrostatic binding monitored. The pH at which highest preconcentration of protein 
on to the underivatised surface was observed, was chosen as the pH for 
irnmobilisation. 
2.7.2 Immobilisation of protein G 
The carboxymethylated dextran matrix was activated by mixing equal volumes of 100 
mM NHS (N-hydroxysuccinimide) and 400 mM EDC (N-ethyl-N- 
(dimethylaminopropyl) carbodiimide hydrochloride) and injecting the mixture over 
the sensor chip surface for 7 minutes at a flowrate of 5 pllminute. The protein G was 
diluted in 10 mM sodium acetate at the optimised pH, at a typical concentration of 50- 
100 pglml. This solution was then passed over the derivatised chip surface for 30-45 
minutes. Unreacted NHS groups were capped, and non-covalently bound protein 
removed by injection of 1 M ethanolamine hydrochloride, pH 8.5, for 7 minutes. 
2.7.3 Inhibition immunoassay for the detection of zilpaterol using R699 anti- 
zilpaterol polyclonal antibody 
Standards of free zilpaterol were prepared at a range of concentrations of between 
0.02 and 500 nglml (final concentrations). Each sample was mixed with a 1/1600 
dilution of polyclonal antibody, and allowed to equilibrate for 30 minutes at 37OC. 
The samples were then passed over the sensor surface in random order. The surface 
was regenerated between cycles by pulses 5 pl of 15 mM NaOH being passed over 
the surface. A calibration curve was constructed by plotting the change in response 
(RU) for each standard against the log of concentration. 
2.7.4 Inhibition immunoassay for the detection of zilpaterol using the anti- 
zilpaterol scFv antibody 
Standards of free zilpaterol were prepared at a range of concentrations between 0.98 
nglml and 1 lg/ml (final concentration). Each sample was diluted 1/10 with cellular 
extract obtained after sonication. (An induced culture was centrifuged at 4000rpm for 
20 minutes and the cell pellets were resuspended in 1/10 the original volume of PBS. 
The suspension was sonicated until cell lysis was achieved and the cell debris 
removed by centrifuging at room temperature at 14,000 rpm for 15 minutes. The 
supernatant, or cellular extract, contained the scFv). These solutions were allowed to 
equilibrate for 30 minutes at 37OC. The assay was then carried out as described in 
Section 2.6.4. 
Chapter 3 
Production and Application of Polyclonal Antibodies and s c f i  
antibody fragments to Zilpaterol 
3.1.1 The Beta-agonists 
Beta-agonists belong to a group of compounds called the catecholamines. They can 
be catalogued into three chemical classes according to their structure: anilines, 
resorcinols and phenols. The beta-agonists enhance growth efficiency by stimulation 
of beta-adrenergic receptors on cell surfaces. Stimulation of these receptors results in 
relaxation of smooth muscles. Beta-agonists are, therefore, frequently used as 
bronchodilators for the treatment of pulmonary disease in humans and animals. 
However, these compounds are also used as growth promoters in livestock production 
due to the anabolic effects exerted when higher doses are administered to the animals. 
P-adrenergic agonists have therefore been called 'repartitioning agents' and cause 
changes, such as increased live weight gain, increased carcass leanness and alterations 
in the ratio of muscle to fat tissue, and animal growth. Treated animals show these 
effects when the applied dose is five to ten times higher than necessary for therapeutic 
treatment (Courtheyn ef aL, 2005). 
Meat products obtained f?om treated animals may pose a potential risk for consumer 
health, mainly in persons with asthma or cardiac lesions. The danger that beta- 
agonists pose was demonstrated by several human poisoning incidences (Brambilla et 
al., 2000). On the basis of such epidemiological evidence, the admistration of beta- 
agonists to food-producing animals as growth promoters has been completely banned 
by Council Directive 96122lEC. Their use has also been prohibited in the USA and 
Asia. 
While clenbuterol is the most effective beta-agonist as a growth-promoting agent, in 
recent years other synthetic beta-agonists such as mabuterol or salbutamol have also 
been used, although their efficiency is lower than clenbuterol. Ractopamine is a beta- 
agonist belonging to the phenolic group. It was commercially developed in the USA 
(Eli Lilly), where its use is authorised, but in the EU the use of ractoparnine is 
completely banned. 
3.1.2 Zilpaterol 
Zilpaterol has appeared as a new beta-agonist developed in South Afiica and was 
approved for use in cattle as a growth promoter in South Africa and Mexico. 
However, its use in the EU, USA and Asia remains illegal. Zilpaterol is a powerful 0- 
agonist, which is more effective than Ratopamine, but only 1/10 as effective as 
Clenbuterol. Structurally, Zilpaterol belongs neither to the group of anilinic 
(clenbuterol-like) nor the phenolic (salbutamol-like) beta-agonists (See Figure 3.1). 
Zilpaterol is capable of redirecting celIuIar metabolism in favour of protein synthesis. 
In muscle tissue, zilpaterol promotes protein synthesis and cell hypertrophy by 
inhibition of proteolysis (rate of protein systhesis is not affected). In adipose tissue, 
zilpaterol promotes lipolysis. In this way, zilpaterol functions as a repartitioning 
agent. 
Figure 3.1 Structure of zilpaterol. 
3.1.3 Detection of Zilpaterol 
Regulatory agencies generally have relied on immunologically based rapid screening 
assays to screen large quantities of samples for the presence of illegal beta-agonist 
residues. However, due to its chemical structure, zilpaterol was, until recently, not 
detected with commonly applied screening and codmatory methods. 
Bocca et al., (2003) developed a method to identify and simultaneously quantify 
clenbuterol-like substances with anilinic moieties and drugs with phenolic and 
catecholic moieties, such as Ractopamine and Zilpaterol, in retinal tissue. After 
extraction in 0.1 N HC1, the samples were cleaned up on C18 non-endcapped solid- 
phase extraction columns and analysed as trimethylchlorosilane derivatives by gas 
chromatographyltandem mass spectrometry, in electron impact mode. At 
concentrations of agonists between 62.5 and 250 ng/g in bovine retina, mean 
recoveries ranged from 85.3 to 94.8%, repeatability was less than 9.6%, and within- 
laboratory reproducibility was less than 10.5%. The detection limits for this assay 
were within the range of 66.3 - 70.4 ng/g. 
Shelver and Smith (2004) reported the development of an ELISA specific to 
zilpaterol. Zilpaterol was reacted with ethyl 4-bromobutyrate followed by refluxing 
in 0.1 M potassium hydroxide. The resulting hapten was reacted with two carrier 
proteins, bovine serum albumin (BSA) or keyhole limpet hemocyanin (KLH), using 
1-ethyl-3-(3-dimethylaminopropy1)-carodiimide (EDC) as an activating agent. 
Immunisation of goats with the zilpaterol-butyrate-KLH resulted in an antibody useful 
for ELISA. Zilpaterol-butyrate-BSA was utilised as a coating antigen for ELISA 
development. The average IC5o derived from the developed zilpaterol immunoassay 
was 3.94 + 0.48 ng/ml (n=25). The antibody did not cross react with other heta- 
agonists. The assay was tolerant of up to 10% (vlv) acetone, ethanol or methanol and 
15% (vlv) of acetonitrile or DMSO. Salt concentrations ranging from 0.05 to 1.OM 
minimally affected Bo (the absorbance reading obtained in the presence of zero 
antigen concentration) or IC5o values. When buffer pH was less than 7 or greater than 
8.8, the lCso values increased in comparison to those measured at pH 7.4. 
A method was developed for the determination of three beta-agonists (one of which 
was zilpaterol) in liver and urine, by liquid chromatography 1 tandem mass 
spectrometry (Blanca et al., 2005). The beta-agonists were identified after clean-up 
with mixed-mode SPE Bond Elut Certify cartridges (6m1, 300mg). This method of 
detection was developed and validated according to the Commission Decision 
200216571EC. Decision limit (CCalpha) ranged from 40 to 110 pglml and 270 to 520 
pg g-l (ppt) for urine and liver, respectively. 
A monoclonal antibody-based ELISA for zilpaterol was developed by Shelver et al., 
in 2005. Mice immunised with zilpaterol-butyrate-keyhole limpet hemocyanin, were 
utilised for monoclonal antibody generation whereas zilpaterol-butyrate-bovine serum 
albumin was used as a coating antigen for ELISA. The resulting zilpaterol-specific 
antibodies underwent sensitivity and isotyping experiments, the best of which show 
high sensitivity to zilpaterol and some interaction with clenbuterol and terbutaliie at 
high concentrations but not with other beta-agonist tested. 
Shelver et ad., 2005 developed a biosensor method to measure zilpaterol in sheep 
urine. A CM-5 sensor chip, which had been previously reacted with ethylenediamine 
to produce an aminoethyl group, was coupled with 4-carboxybutyl zilpaterol activated 
using EDC/NHS. Five polyclonal and four monoclonal antibodies were screened for 
their suitability to detect low levels of zilpaterol using the biosensor technology. 
Total binding was greater for polyclonal than monoclonal antibodies, but a more 
concentrated antibody solution was required for polyclonal antibodies. A fixed 
antibody concentration and various concentrations of zilpaterol were injected to 
obtain a standard curve for each antibody to allow Bo (the absorbance reading 
obtained in the presence of zero antigen concentration) in repeated experiments 
extending at least 6 hours. A measure of non-specific binding allowed the assessment 
of the specificity of the antibody-immobilised ligand interaction. The effect of 
vzuying concentrations of urine on Bo and ICSO (50% of the mean absorbance at each 
antigen concentration / absorbance in the presence of zero antigen concentration) 
was evaluated to assess the degree of matrix effect that would be present in an assay. 
Based on these criteria the most promising antibody was selected for further 
evaluation. This antibody had good sensitivity with IC5o = 4.47 + 0.41 ng/ml (n=l I). 
Both intra- and inter-assay variation studies showed excellent recovery and 
reproducibility for concentrations between 2 nglml and 8 ng/ml. A comparison of the 
biosensor method with a previously developed ELISA demonstrated that both 
methods give equivalent results (slope of the correlation plot = 1.02) with a high 
correlation (2 = 0.91). 
Affinity-based sensors monitor the binding between two molecules. Such interactions 
may include enzymes, antibodies, whole cells, receptors nucleic acids and antigens 
(McCormack et aL, 1998). Recently, several commercial biosensors have been 
developed using surface plasmon resonance (SPR) technology as their detection 
method. In particular, the Biacore SPR-based biosensor has become a very important 
tool in the detection of a number of analytes, i.e. "real-time" observation of a specific 
biological event e.g. antibody-antigen interaction (Leonard et al., 2003). 
The principle behind SPR is described in the context of Biacore for convenience. At 
an interface between two media of different refractive indices, (e.g. glass and water), 
light being emitted from the side of the higher refractive index is partly reflected and 
refracted. Above a certain critical angle of incidence, the light is totally internally 
reflected and no light is refracted across the interface between the two surfaces of the 
different refractive indices. 
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Figure 3.2 Under conditions of total internal refection at a metal-coated interface, and evanescent 
wavepropagates into the medium of lower refractive index on the non-illuminatedside. 
Under total internal reflection (TIR) conditions, an electromagnetic field component 
1- 
called the evanescent wave penetrates into the medium of lower refractive index a 
short distance in the order of one wavelength (Figure 3.2). As the evanescent wave 
moves further away from the interface into the lower dense medium, the wave decays 
exponentially. The interface between the media is coated with a thin layer of metal 
(in the case of Biacore, this metal layer is gold), containing electron clouds at the 
surface. The passage of the evanescent wave through this metal layer causes the 
plasmons to resonate which results in a quantum mechanical wave known as a surface 
plasmon. Some of the energy of the reflected light (incident light) is taken up by the 
surface plasmon wave, resulting in a dip in the intensity of reflected light at a certain 
angle being observed (Panayotou et al., 1993). The incident light angle at which this 
dip is observed is known as the SPR angle. The SPR angle is dependent on a number 
of factors i.e. properties of the metal film, the wavelength of the polarisation of 
incident light and the refractive index of the media on either side of the metal film. In 
real-time BIA, these properties are kept constant. The SPR signal can then be used to 
monitor the refractive index of the aqueous layer immediately adjacent to the gold 
metal layer. Changes in the refractive index are a direct result of changes in the mass 
or concentration on the surface of the chip and this characteristic of SPR has been 
used to monitor biological interactions. The change in reflected light is interpolated 
as a sensorgram. 
The Biacore biosensor has a number of major advantages compared with conventional 
detection techniques. The absence of a need for labelling is of major significance as it 
minimises interference with the binding interaction being studied and also eliminates 
expensive and time-consuming purifications in many situations. Real-time analysis of 
interactants is also one of the main advantages of the Biacore instrument as 
interactions may now be monitored as they occur, providing valuable diagnostic 
information as well as kinetic data. Further advantages include the ability of the 
instrument to allow rapid and automated analysis. 
Research has now focused on more mechanised, rapid and reliable assays. Biosensor 
technology has now emerged as a useful tool in immunodetection strategies for a 
variety of analytes. Biosensors use a combination of biological receptor compounds 
(antibody, enzyme, nucleic acid, etc.) and the physical or physico-chemical transducer 
directing, in most cases, "real-time" observation of a specific biological event e.g. 
antibody-antigen interaction (Leonard et aL, 2003). 
3.2 Results 
3.2.1 Development of a competitive enzyme-linked immunosorbent assay 
(ELISA) for zilpaterol 
Serum containing anti-zilpaterol polyclonal antibodies was produced by Dr. Lisa 
Connolly of Queens University, Belfast. This polyclonal antibody was designated 
R699. A competitive ELISA was developed for the detection of free zilpaterol in 
solution using this antiserum. 
3.2.1.1 Competitive checkerboard ELISA of R699 polyclonal antibody to 
determine optimal antibody and zilpaterol concentrations 
The optimal working dilutions of serum and of fiee zilpaterol were determined using 
the protocol described in Section 2.3.3. The results were plotted as shown in Figure 
3.3. The optimal serum coating dilution was found to be 111600. (Serum dilutions 
between 111600 and 11102400 were made due to the limited amount of serum 
available). The optimal range of free zilpaterol concentrations for use in the 
development of a competitive ELISA was determined to be between 0.48 to 500 
nglml. 
3.2.1.2 Polyclonal antibody ELISA buffer optimisation 
3.2.1.2.1 Competitive ELISA to determine optimal coating buffer 
The format of the competitive ELISA performed to determine the optimal coating 
buffer was described in Section 2.2.4.1. The results were plotted as shown in Figure 
3.3. The optimal serum coating dilution buffer was found to be sodium acetate. 
3.2.1.2.2 Competitive ELISA to determine optimal zilpaterol dilution buffer 
The ELISA protocol for the determination of the optimal zilpaterol dilution buffer is 
described in Section 2.2.4.2. The results were plotted as shown in Figure 3.4. It was 
determined that sodium acetate was the optimal buffer. 
3.2.1.3 Development of a competitive ELISA for the detection of zilpaterol 
The immunoassay format described in Section 2.2.5 was used to determine the 
optimal range of detection of free zilpaterol. In order to determine the inter-day assay 
variation, the ELISA was then repeated three times over three separate days. The 
normalised mean values, which were calculated as the mean absorbance at each 
antigen concentration / absorbance in the presence of zero antigen concentration 
(AIAO) over the three days were used to construct a calibration curve for the interday 
assay. Using BIAevaluation 3.1 software the calibration curve was plotted using the 
four-parameter equation. Comparisons were made between each zilpaterol 
concentration and its back-calculated counterpart concentration, as calculated from 
the calibration curve. The percentage accuracy for each concentration was calculated 
as the difference between the two (Table 3.1). Using these accuracy percentages to 
calculate the limit of quantitation, the range of detection for fiee zilpaterol was 
defmed as 0.24 to 31.25 ndml (Figure 3.5). The coefficients of variation (CVs) 
between the three replicates of each cell concentration were determined by expressing 
the standard deviation as a percentage function of the mean. The CVs are shown in 
Table 3.1. The interday CVs ranged from 2.75 to 12.5%. 
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Figure 3.2 Competitive checkerboard ELISA for free zilpaterol. Dilutions ofR699polyclonal antibody 
rangingfrom 1/1600 to 1/102400 were used to coat the wells of a microtitreplate. Free zilpaterol was 
added to the plate in concentrations ranging from 0.48 to 500 ng/ml. Zilpaterol-HRP, at a 1/4000 
dilutzon @nu1 concentration) was added simultaneously and allowed to compete with thejive zilpaterol 
for binding to the antibody. The normalised mean values are the mean absorbance at each antigen 
concentration / absorbance in the presence of zero antigen concentration (A/Aa) over the three dqs .  
An antibody dilution of 1/1600 provided the best competitive results, while free zilpaterol dilutions of 
0.48 to 500 ndml were deemed optimal to test the range of sensitiviw of the antibody (Serum dilutions 
between 1/1600 and 1/102400 were made due to the limited amount of serum available). 
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1 Figure 3.3 Competitive ELISA with a 1/4000 dilution of zilpaterol-HRP conjugate, shaving the I comparison of assay sensitivity between four dzyerent coating buffms when R699 polyclonal antibo4 I was diluted 1/1600 in each buff& Sodium acetate proved to be the optimal coating buffer (HA0 I represents the mean absorbance at each antigen concenhation / absorbance in the presence of zero I antigen concenhation. 
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Figure 3.4 Competitive ELISA with zilpaterol-HRP conjugate, showing the comparison of assay 
sensitivity between four dzrerent zilpaterol diluting buffers. Sodium acetate proved to be the optimal 
dilution buffer. 
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Figure 3.5 Interday assay calzbration curve for the R699 anti-zilpaterolpolyclonal antzbody in sodium 
acetate bufer A #-parameter equation was fitted to the data set using BIAevaluation 3 I software. 
The inter-ussay coeficients of variance are tabulated in Table 1. Each poznt on the curve is the mean 
of three replicate measurements analysed over three days. The range of detection for ffee zzlpaterol 
was calculated to be 0.24 to 31.25 ng/ml. 
Table 3.1 Interday assay coeficients of variation (CV's) and percentage acmracies for R699 antz- 
zilpaterol polydonal antibody in sodzum acetate buffer. Interday studies were conducted and 
coejj?cients of variance (a quantitatwe measure of preciston) calculated using the equation % CV = 
(S.D/Mean) x 100 where for intermediate precision (interday), the S.D as computedfrom replicate 
(three replicates) analyses over three validatzon runs on three separate days. The percentage accuracy 
for each concentration was calculated as the darerenee between each zilpaterol concentration and its 
back-calculated counterpart concentration, as determinedfrom the calibration curve. 
Conc. (nglml) 
1000 
500 
Back calculated 
cone. (nglml) 
802.94 
458.53 
Calculated 
mean 5 S.D 
0.02 2 0.02 
0.19 + 0.02 
Coefficient of 
variation (%) 
8.75 
12.59 
Accuracy (%) 
119.06 
108.29 
3.2.2 Cross-reactivity studies 
The specificity of the polyclonal antibodies to zilpaterol is critical for the performance 
of the immunoassay. Cross reactivity studies were carried out with four P-agonists, 
and a number of other potential cross-reactants. Several related steroid compounds 
were chosen on the basis of their possible presence in real samples for analysis. 
These were zeranol, a-estradiol, P-estradiol, 19-nortestosterone and norethisterone. 
The ELISA was performed as described in Section 2.3, with equal concentrations of 
the drug to be tested added in place of zilpaterol. The displacement method described 
by Miller and Valdes (1993) was used to accurately estimate the levels of cross- 
reactivity, with the ICso value defined as the analyte concentration that results in 50% 
displacement, or inhibition of the antibody, and the IC90 value defined as the analyte 
concentration that results in 90% displacement, or inhibition. Levels of cross- 
reactivity at IC50 (CRso) were 100-fold the ratio between the ICso values of zilpaterol 
and of the cross-reactant. ICgO (CR90) levels of cross-reactivity were 100-fold the 
ratio between the IC9o values of zilpaterol and of the cross-reactant. Tne competitive 
ELISA for zilpaterol was repeated and plotted for comparison. The levels of cross- 
reactivity at the IC5o (CR5o) and (CRgo) are shown in Tables 3.2 and 3.3. 
Table 3.2 Cross-reactivity and specifcity studies on R699polyclonal anti-zilpaterol antiboQ against 
four Pagonists. The cross-reactivity potential was approximated at the ICpo value, which rs the 
conceniranon of drug detectable at 90% NAo, and the ICjo value, whzch rs estimated at 50% NAu The 
CRgo and CRjo were then expressed as 100-fold the ratio of zzlpaterol and of the cross-reactant. 
Drug ( ~~~o~(ng/rnl) ( 1~so~(ng/rnl) ( CRsoC(%) 1 cRmd (%) 1 
I I I I 
Zilpaterol 
I I I I 
Mabuterol 
8 
Ractopamine I I I 
I I I 
Salbutamol 1 I 200 - 0.1 - 
0.2 
t 
Clenbuterol / I I I 
a Least detectable dose calculated at 90% A/Ao 
50% inhibition concentration (50% A/Ao) 
Percentage cross-reactivity determined at ICso 
Percentage cross-reactivity determined at ICgo 
200 
- >loo0 
1 
7 
- 
- 
- 3 
100 
- 
- 
100 
0.1 - 
Table 3.3 Cross-reactivily and spec~jkiiciiy studies on R699 polyclonal anti-zilpaterol antiboQ against 
several other potential cross-reactants The cross-reactivity potential was approximated at the ICg0 
value, which is the concenfratzon of drug detectable at 90% A/Ao, and the ICxo value, whzch is 
estmated at SO% MAo. The CRgo and CRJo were then expressed as 100,fold the ratio of zdpaterol and 
of the cross-reactant. 
Drug I IC," (ng/ml) I 1c5ob (ng/ml) I C%oc (%) I cR5od (%I / 
I I I I 
Zilpaterol 
I I I I 
a-estradiol 
I I I I 
a Least detectable dose calculated at 90% A/Ao 
0.2 
Zeranol 
P-estradiol 
Norethisterone 
50% inhibition concentration (50% NAo) 
>lo00 
C Percentage cross-reactivity determined at ICso 
1 
>lo00 
>lo00 
>lo00 
Percentage cross-reactivity determined at IC90 
- 
100 
- 
- 
- 
100 
- - 
- 
- 
- 
- 
- 
- 
3.2.3 Development of a Biacore-based inhibition immunoassay for zilpaterol 
3.2.3.1 CM5 Biacore chip directly immobilised with zilpaterol 
A CM5 Biacore chip, which had been directly immobilised with zilpaterol, was 
obtained from Dr. Lisa Connolly of Queens University, Belfast. 
3.2.3.2 Inhibition immunoassay for the detection of zilpaterol using R699 anti- 
zilpaterol polyclonal antibody 
An inhibition assay was performed for the detection of free zilpaterol using the 
protocol described in Section 2.6.4. All dilutions were made in HBS buffer. Once 
equilibrated, the samples were passed over the sensor surface in random order, 
followed by regeneration with 15 mM NaOH. Interday variability studies were then 
carried out to estimate the reproducibility of the assay. To estimate the interday assay 
variation, the inhibition assay was conducted three times over three different days and 
the mean value of the response units of bound antibody for each zilpaterol 
concentration was plotted against the free zilpaterol concentration. Comparisons were 
made between each zilpaterol concentration and its back-calculated counterpart 
concentration, as determined from the calibration curve. The percentage accuracy for 
each concentration was calculated as the difference between the two (Table 3.4). 
These accuracy percentages were used to calculate the limit of quantitation. This 
study showed that the R699 polyclonal anti-zilpaterol antibody had a range of 
detection of 490 pglml to 62.5 nglml with CVs of 2.24 to 7.89 %. Figure 3.6 shows 
the interday assay curve. The CVs obtained are shown in Table 3.4. 
3 I 
0.01 0 1 1 10 100 1000 
Log of free zilpateml concentration (nglrnl) 
Figure 3.6 inter-day Biacore inhibition assay to defermine the range of detection offree zilpaterol 
using R699 anti-zilpaterolpolyclonal antibody. Zhe range of detection was found to befi.om 490pg/ml 
to 62.5 ng/mJ. 
Table 3.4 Interday assay co@cienfs of variation (CV's) andpercentage accuracies for the inhibitron 
assay developed on Biacore 3000 using R699 anti-zrlpaterolpolyclonal ant~body. CV's were measured 
uszng the equation % CV = (S.D./Mean) x 100 where for rntermediate precision (interday), the S.D. rs 
computedfrom replicate (three replicates) analyses over three validation runs on three separate days 
The percentage accuracy for each Concenhatlon was calculated as the dijjerence between each 
zilpaferol concenfratlon and its back-calculated counterpart concenhation, as determined from the 
calibration cuwe 
Conc. (ndml) 
500 
250 
Back 
calculated 
conc. (ngtml) 
d a  
336.49 
Mean 5 S.D. 
R/Ro 
0.06 2 0.0 
0.07 + 0.01 
Coefficient of 
variation (%) 
Accuracy 
("A) 
0.00 
5.33 
0.00 
65.40 
3.2.4 The production of a murine scFv antibody library to zilpaterol 
3.2.4.1 Immunisation of mice with zilpaterol-HSA and isolation of spleenocyte 
mRNA 
Spleen cells isolated from mice immunised with zilpaterol-HSA were used to generate 
rnRNA. This was carried out and the mRNA provided by Dr. Paul Dillon, DCU. 
3.2.4.2 Reverse transcription of mouse spleen mRNA 
Reverse transcription to synthesise cDNA was carried out on the mRNA provided as 
described in Section 2.3.2. 
3.2.4.3 Amplification of antibody light and heavy chain genes 
Amplification of the variable regions of the light and heavy cham genes was camed 
out using the protocol described in Section 2.3.3. A single band of approximately 400 
bp for both the heavy and light chain genes was amplified from the cDNA. To 
amplify light chain genes the VL back primer mix was paired with five VL forward 
primers and to amplify heavy chain genes the VH back mix was paired with four VH 
f o m d  primers. In all cases, the first PCR amplification yielded sufficient amounts 
for cloning, with a sharp band produced at the predicted band of approximately 400 
bps for both the VL and VH genes (Figure 3.7). These fragments were purified from 
the gel, as described in Section 2.3.3.4, and their concentration determined (Table 
3.5). 
3.2.4.4 Splice by overlap extension (SOE) PCR 
The amplified VL and VH domains were linked together by SOE-PCR after 
purification to produce a combined molecular weight fragment of approximately 800 
bp (Figure 3.8). 
3.2.4.5 Digestion and ligation of pAKlOO vector and SOE-PCR products formed 
by Linking antibody light and heavy chain genes 
The pAK 100 vector and SOE-PCR products formed by linking antibody light and 
heavy chain genes were digested with S'restriction enzyme, as described for both in 
Section 2.3.6. Figure 3.9 shows the digested pAKlOO product. The digested pAK 
100 and SOE-product were purified from the gel, as described in Section 2.3.3.4, and 
the concentrations determined (Table 3.5). After purification, the SOE-PCR fragment 
was ligated into the pAK 100 vector at a molar ratio of vector to insert of 1.5:1, as 
described in Section 2.3.7. 
3.2.4.7 Transformation of E. coli XL1-Blue supercompetent cells with pAK 100 
vector containing light and heavy chain gene 
Supercompetent E. coli XL1-Blue cells were used for the production of a recombinant 
antibody library to zilpaterol using the procedure described in Section 2.3.9. Ligation 
reactions of pAKlOO vector and SOE-PCR products were transformed resulting in the 
production of a zilpaterol recombinant library consisting of approximately 5 x lo3 
transformants. 
- Non-specific 
PCR products 
gure 3.7 GeI picture showing the amplVication of murine light and heavy chain specifically 
nplified Lanes: (I) Promega IkB DNA ladder; lanes (2-6) Amplifid 400 bp VHfiagment; lanes (7- 
Amplifed 400 bp V~fragment. 
70E-PCR 
lroduct 
BOO bp) 
Figure 3.8 Gelpicture showing undigestedSOEPCRproduct. Lanes: (I) Promega IkB DNA ladder; 
lanes (2-5) Amplifed VL and VH domains linked by SOE-PCR. 
g A K  100 vector 
(digested) 
Figure 3.9 Restriction digestion ofpAK 100 vector. Lanes. (I) Bioline Hyperladder; lanes (2-4) The 
drgestedpAK 100 vector. 
Table 3.5 Concentrations of DNA of the various components for library production 
I Samples 
I 
Concentration of DNA (ng/pI) 
Zilpaterol Heavy chain Mouse 
Zilpaterol Light chain Mouse 
Digested SOE-PCR product 
40 
50 
40 
, 
pAK 100 vector 60 
3.2.5 Production of single chain Fv antibodies to zilpaterol 
3.2.5.1 First round selection and screening of functional scFv sequences to 
zilpaterol from zilpaterol recombinant library using phage ELISA 
Production of phagemid particles from the zilpaterol recombinant antibody library 
was carried out as described in Section 2.4.1. After transformation of the ligation 
reaction into competent E. coli XL1-Blue cells, the resulting phage particles were then 
used in the first round of affinity selection of scFv antibodies by panning with 
zilpaterol-HSA as described in Section 2.2.4. After panning and elution from the 
immunotube a titration was carried out on the remaining phage resulting in a 1 x 10' 
phage particle count. 
95 individual clones from the zilpaterol recombinant antibody library selected after 
the first round of panning, were grown separately and infected by helper phage, as 
described in Section 2.4.5. The recombinant scFvs, displayed on the surface of 
filamentous phage, were screened on a plate coated with zilpaterol-HSA (for antigen 
biding) in a typical phage ELISA as described in Section 2.4.6. Results from the 
phage ELISA showed that 8 of the clones analysed possessed affmity to the conjugate 
(Figure 3.10). 
Eight positive clones, Al, A9, B1, E2, H5, E7, H7 and Dl1 were selected on the 
bases of the strength of their absorbance readings for characterisation with respect to 
their affinity for free zilpaterol. The scFv-displaying phage produced from these 
clones was used to conduct a simple competitive ELISA with free zilpaterol. Four of 
the eight clones (A9, B1, E2 and E7) demonstrated competition for free zilpaterol 
(Figure 3.1 1). 
.... ~~~- 
Column number 
Figure 3.10 Graphical representation of absorbance data from an ELISA carried out on 95 clones 
after the first round ofpanning. A1, A9, BI, E2, H5, E7, H7 and Dl1 scFv antibody clones were 
picked in order to stuQ their abilfg to bindtopee zilpaterol. 
1 ,- I Concentraflon Of free zilpatewl I 
A1 B1 E2 H5 E7 H8 A9 Dl1 
Antibody clone number 
Figure 3.12 Bar chart representing the results obtainedfrom a competitive ELISA of eight phage-scFv 
antibody fragments (clones selectedfrom panning, Figure 3.10) with free zilparerol. ScFv clones BI, 
E2, E7 and A9 demonshated better binding capabilities than the other clones, and were therefore 
chosen forhrther study. 
3.2.5.2 Digestion of A9, B1, E2 and E7 scFv antibody light and heavy chain genes 
and pAK 400 vector for production of soluble scFv antibody 
Antibody light and heavy chain genes from clones A9, El ,  E2 and E7 were digested 
with SJiI restriction enzyme as shown in Figure 3.12. The two main bands represent 
the digested pAK 100 vector, and the scFv fragment. The pAK 400 vector is used for 
the production of soluble scFv fragments. The digested pAK 400 vector is shown in 
Figure 3.13. This DNA was gel-purified as described in Section 2.3.3.4. Light and 
heavy chain genes from clones A9, B1, E2 and E7 were ligated into the digested pAK 
400, as described in Section 2.4.9. These four ligation products were transformed into 
JM83 competent cells (Section 2.4.11), resulting in the production of four clones 
capable of producing soluble scFv antibodies. 
3.2.5.3 Soluble expression of A9, B1, E2 and E7 scFv antibodies 
Soluble scFv antibodies fiom A9, El,  E2 and E7 clones were produced in supernatant 
(see Section 2.4.12). 
Digested 
pAK 100 
vector 
800 bp 
scFv 
fragments 
Figure 3.12 Restriction drgestion ofpAK 100 vector puriJedfrom A9, Bl,  E2 and E7 clones Lanes: 
( I )  Bioline Hyperladder; (2-3) A9 digestedpAK 100 and scFvfragment; lanes (4-3) B1 dzgestedpAK 
100 and scFv fragment; lanes (6-7) E2 dzgested pAK 100 and scFv fragment and lanes (8-9) E7 
digested pAK 100 and scFv fragment. 
Digested pAK 
400 vector 
Figure 3.13 Restriction digestion ofpAK 400 vector. Lanes: (1) Broline Hyperladder; lanes (2-3) 
DfgestedpAK 400fragment. pAK 400 was restricted rn order to provide en& to whrch the digested 
scFv DNA fragments could be annealed. 
3.2.6 Development of an scFv-based competitive enzyme-linked immunosorbent 
assay (ELISA) for zilpaterol 
3.2.6.1 Checkerboard ELISA for determination of optimal zilpaterol coating 
concentration and optimal scFv antibody dilution 
The working dilution of these antibodies was determined using the format already 
discussed in Section 2.4.13. Zilpaterol-HSA was coated on the wells of four 
microtitre plates at three different concentrations (5 pglml, 2.5 pg/ml, 1.25 pglml), 
with one row of wells per concentration. A fourth row of wells was left uncoated, and 
all four rows were blocked with 5% (wlv) milk marvel. Dilutions of cellular extract 
from the four clones A9, B1, E2 and E7 containing the scFv were prepared, with 
concentrations ranging from neat to 11100. Each dilution of antibody was added to 
each concentration of conjugate on the microtitre plates. The results for each of the 
four clones were plotted in Figure 3.14. The scFv produced from the B1 clone gave 
the strongest signal and was therefore chosen for further analysis and assay 
development. For the B1 scFv antibody, the optimal conjugate coating concentration 
was found to be 5 pglml, and the optimal scFv antibody dilution was determined to be 
112. 
3.2.6.2 Interday competitive ELISA for B1 scFv antibody characterisation 
A competitive ELISA using the optimal coating concentration and scFv antibody 
dilution was performed as described in Section 2.4.15. In order to determine the 
inter-day assay variation, the ELISA was repeated three times over three separate 
days. The normalised mean values, which were calculated as the mean absorbance at 
each antigen concentration / absorbance in the presence of zero antigen concentration 
(A/Ao) over the three days were used to construct a calibration curve for the interday 
assay. Using Biaevaluation 3.1 software the calibration curve was plotted using the 
four-parameter equation. Comparisons were made between each zilpaterol 
concentration and its back-calculated counterpart concentration, as calculated from 
the calibration curve. The percentage accuracy for each concentration was calculated 
as the difference between the two (Table 3.6). Using these accuracy percentages to 
calculate the limit of quantitation, the l i t  of detection for free zilpaterol was defined 
as 78 n g h l  (Figure 3.15). The coefficients of variation (CVs) between the three 
replicates of each cell concentration were determined by expressing the standard 
deviation as a percentage function of the mean. The CVs are shown in Table 3.6. 
The interday CVs ranged from 1.66 to 9.48 %. 
- 
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Figure 3.14 a Checkerboard ELISAs performed using antibodies A9 (top ofpage) and BI(above) to 
determine the optimal zrlpaterol coating concentration and optimal scFv antibody dilution for use. 
ScFv produced from the BI clone gave the strongest signal. The optimal conjugate coatrng 
concentration for the BI scFv was found to be 5 pdml, and the optimal scFv antibody drlution was 
determined to be 1 in 2 
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Figure 3.14 b Checkerboard ELISAs performed using antibodies E2 (top ofpage) and E7 (above) to 
determine ihe optimal zrlpaterol coating concentration and optimal scFv antibody dilution The 
response observed using these antibodies highlrghtedB1 (Figure 3.13 a) as the best antibody for a s s q  
development 
Log of free zilpaterol concentration (nglml) 
Figure 3.15 Interday assay calibration curve for the B1 scFv antibody A 4-parameter equatron was 
fitted to the data set uszng BIAevaluation 3.1 sofhuare. The inter-assay coeficients of var~ance are 
tabulated in Table (3 6). Each pornt on the w e  is the mean of three replicate measurements analysed 
over three days. 
Table 3.6 Interday assay coeficients of variation (CVS) andpercentage accuracies for the BI scFv 
antibody. Interday studaes were conducted and coefficients of variance (a quantitative measure of 
precision) calculated using the equation % CV = (S.D./Mean) x 100 where for intermediate precision 
(interdad, the S D. is computed@om replicate (three replicates) analyses over three valzdation runs on 
three separate days. 
Cone. Back calculated Calculated Coefficient of Accuracy (96) 
3.2.7 Development of a Biacore-based inhibition immunoassay for zilpaterol 
3.2.7.1 CMS Biacore chip directly immobilised with zilpaterol 
A CM5 Biacore chip, which had been directly immobilised with zilpaterol, was 
obtained kom Dr. Lisa Connolly of Queens University, Belfast. 
3.2.7.2 Inhibition immunoassay for the detection of zilpaterol using the anti- 
zilpaterol scFv antibody 
The protocol used to conduct an inhibition assay for free zilpaterol using the anti- 
zilpaterol scFv antibody is found in Section 2.6.5. To determine the interday assay 
variation, individual assays were performed each day for five days. The mean and 
percentage CV of the five results generated for each of the five assays was 
determined. Inhibition was observed for each individual assay. However, the 
percentage CV for the five results did not allow an accurate calibration curve to be 
constructed (results not shown). Figure 3.16 shows a single inhibition assay 
performed on the Biacore 3000. Figure 3.17 shows the linear range of the Biacore- 
based inhi5ition assay shown in Figure 3.10. Comparisons were made between each 
zilpaterol concentration and its back-calculated counterpart concentration, as 
calculated &om the calibration curve. The percentage accuracy for each concentration 
was calculated as the difference between the two. Using these accuracy percentages 
to calculate the limit of quantitation, the range of detection for free zilpaterol was 
defined as between 15.6 and 125 nglml. 
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Figure 3.16 Bracore-based inhibition assay to determine the range of detectton offree zilpaterol using 
the anti-zilpaterol scFv antibody. The range of detection was found to befrom 15.6 to 125 ng/ml (R/Ro 
represents the mean response unit at each antigen concenhatron /response unit in the presence ofzero 
antigen concenhation). 
Figure 3.17 The linear range of the Biacore-based inhzbitzon assay shown in Figure 3.16, with the 
range of detectionfrom 15.6 to 125 ng/ml. 
3.2.7.3 Biacore-based cross-reactivity study of s c f i  antibody 
Cross-reactivity potential of the scFv was determined against four p-agonists, 
clenbuterol, mabuterol, salbutamol and ractopamine, as well as several other related 
steroid compounds in a Biacore inhibition assay format. The inhibition assay was 
performed as described in Section 3.2.7.2, with equal concentrations of the drug to be 
tested added in place of the zilpaterol. The displacement method described by Miller 
and Valdes (Miller et al., 1992) was used to accurately estimate the levels of cross- 
reactivity, with the ICso value defied as the analyte concentration that results in 50% 
inhibition of the antibody and the IC90 value defined as the analyte concentration that 
results in 90% inhibition. Levels of cross-reactivity were estimated at the ICjo (CRso) 
as 100-fold the ratio between the ICSo values of zilpaterol and of the cross-reactant. 
(CRw) levels of cross-reactivity were estimated as 100-fold the ratio between the 
IC90 values of zilpaterol and of the cross-reactant. Levels of cross-reactivity at the 
ICjo (CRjo) and (CR90) are shown in Tables 3.7 and 3.8. 
Table 3.7 Cross-reactrvity and specflcity studies on scFv antibody against four ,l%agonists. The cross- 
reactiv~ty potential was appraximated at the ICgo value, which is the concenhation of drug detectable 
at 90% &Ah and the ICSO value, whrch is estrmated at 50% A/AO. The Cfio  and Cfio were then 
expressed as 100-fold the ratio of zibaterol and of the cross-reactant. 
Drug I ICsoa (ng/ml) I 1c5nb (ng/ml) I CR~O' (%) I cRsnd (%) I 
Ractopamine I I 1 I 2500 - 1 - 
I I I I 
I 
Clenbuterol 1 I I I 20 100 - 
Zilpaterol 
a Least detectable dose calculated at 90% A/Ao 
50% inhibition concentration (50% MAo) 
C Percentage cross-reactivity determined at ICso 
Percentage cross-reactivity determined at ICso 
20 
Salbutamol 1 1 
50 
- 30 66 
100 100 
Table 3.8 Cross-reactivity and specific@ studies on scFv antibody against several other potential 
cross-reactants The cross-reactivity potential was approximated at the ICyo value, which is the 
concentration of b u g  detectable at 90% A/A0 and the ICJO value, whzch rs estimated at 50% MAn The 
CRYO and CRjo were then expressed as 1 OO-foId the rat10 of zrlpaterol and of the cross-reactant. 
a Least detectable dose calculated at 90% NAo 
50% inhibition concentration (50% A/Ao) 
C Percentage cross-reactivity determined at ICso 
Percentage cross-reactivity determined at ICgo 
3.3 Discussion 
This chapter includes all assay development undertaken using both polyclonal and 
scFv antibodies to zilpaterol. 
The anti-zilpaterol antibody R699 was used to develop a competitive ELISA for the 
detection of zilpaterol. This assay involved immobilisation of the polyclonal antibody 
onto the surface of a microtitre plate, followed by simultaneous addition of a fixed 
concentration of HRP-labelled zilpaterol and varying concentrations of free zilpaterol. 
The signal produced was inversely proportional to the concentration of free zilpaterol 
present in the sample. Initial investigation work was carried out to determine the 
optimal conditions for this assay. A competitive checkerboard ELISA was conducted 
to determine the optimal concentrations of coating antigen and of antibody for use in 
ELISA. The limits of detection in competitive ELISA's are a function of the antibody 
affmity, and the equilibrium between both the free and immobilised conjugate. As a 
result, too high a concentration of coating conjugate will shift the binding equilibrium 
in favour of binding to the ELISA plate and cause reduced sensitivity to free antigen 
in solution. Similarly, the concentration of antibody used must be the l i i t ing  factor. 
If this were not the case, antibody would be capable of binding to free drug and bound 
conjugate in excess. Therefore, it is essential to optimise both the loading 
concentration of solid-phase conjugate and the dilution of antibody. The optimal 
serum coating dilution was found to be 111600. The optimal range of free zilpaterol 
concentrations for use in the development of a competitive ELISA was determined to 
be between 0.24 and 500 nglml, while a dilution of 114000 of zilpaterol-HSA was 
optimal for use. 
Further competitive ELISAs were then performed using various different buffering 
solutions (Sections 2.3.1.3.1 and 2.3.1.3.2) to determine the optimal coating and 
dilution buffer for use with the polyclonal antibody and zilpaterol, respectively. 
Differences in the binding capabilities of the polyclonal antibody to the immobilised 
zilpaterol conjugate were compared. Sodium acetate proved to be the optimal buffer 
for use in the assay. 
Once these factors had been determined, a model competitive assay was developed 
where standards of free zilpaterol ranging from 0.48 to 500 nglml were prepared and 
mixed with a 112000 dilution of zilpaterol-HSA (final dilution 114000). Both the free 
and HSA-bound zilpaterol competed within this range. Free zilpaterol showed a 
range of detection between 0.24 to 31.25 nglml. The assay displayed excellent 
recognition of the unconjugated zilpaterol molecules and showed very low limits of 
detection. Interday assay variability statistics were then analysed in an attempt to 
assess the reproducibility of the assay. Interday assay coefi'icients of variation (CV's) 
were found to be between 2.75 and 13.24% (Table 3.1). This result indicates that this 
polyclonal antibody can be used to generate an accurate, specific and reproducible 
assay. 
One of the initial steps in designing an immunoassay is the assessment of reactivity 
towards structurally similar molecules. (Wild, 1994). Cross reactivity is defined as a 
measure of the antibody response to structurally similar molecules. Serial dilutions of 
the cross-reactive analyte of interest are prepared with similar dilutions of specific 
antigen. A competitive ELISA carried out as described in Section 2.2.5. Tables 3.2 
and 3.3 show the I C 9 ~  value, which is the concentration of drug detectable at 90% 
NAo, and the ICso value, which is estimated at 50% NAo. These values were 
calculated using the displacement method described by Miller and Valdes (Miller et 
al., 1992). Competitive assays were carried out with several other p-agonists, in 
addition to several other potential cross-reactants. Clenbuterol, mabuterol, salbutanol 
and ractopamine (the P-agonists), along with alpha-estradiol, 19-nortestosterone, 
zeranol, beta-estradiol and norethisterone were used in place of zilpaterol in the 
competitive assay to ascertain cross-reactivity. IC90 values, which is the 
concentration of drug detectable at 90% NAo, and the ICso values, which is estimated 
at 50% NAo, for each of these beta agonists were calculated (Table 3.3). Low cross- 
reactivity levels indicate that the scFv is specific to the structure unique to the 
zilpaterol molecule. 
The next step was the development of a Biacore-based Inhibition immunoassay for 
the detection of zilpaterol using R699 anti-zilpaterol polyclonal antibody and a CM5 
Biacore chip, which had been directly immobilised with zilpaterol. 
A model inhibition assay was developed (described in Section 2.6.4) for free 
zilpaterol. Standards of zilpaterol ranging fiom 0.02 to 500 ng/ml (final 
concentrations) were mixed with a 111600 dilution (final) of R699 antibody. These 
mixtures were allowed to incubate at 37OC for 30 minutes followed by injection over 
the zilpaterol-immobilised surface for 3 minutes. The surface of the chip was 
regenerated between cycles by passing pulses of 5 pl of 15 mM NaOH over the 
surface. The antibody response to the surface is inversely proportional to the 
concentration of free drug in solution. These binding responses were plotted in Figure 
3.6 and showed that the detection range of R699 for free zilpaterol was between 490 
p g d  to 62.5 ng/ml (Table 3.4). 
Production of an scFv antibody fragment specific for zilpaterol and use of this 
fragment in the development of an assay for the detection of zilpaterol was then 
carried out. The advantage in production and use of a recombinant antibody fragment 
in assay development is that the biding capability of the fragment can be improved 
using genetic engineering techniques (as outlined in the introductory chapter). The 
antibody fragments described in this chapter are the first recombinant antibodies 
produced to zilpaterol to my knowledge. The initial stages for the isolation of a 
specific scFv antibody fragment involved the imrnunisation of mice with zilpaterol- 
HSA and sacrifice of the animal once a suitable immune response had been generated. 
%e spleen was subsequently removed and mRNA isolated from these spleen cells. 
This was carried out by Dr. Paul Dillon. 
The isolated mRNA was used in the production of cDNA followed by the 
amplification of the light and heavy chain genes. The set of primers used were 
produced by Krebber et al. (1997). They incorporate all mouse VH, V ~ a n d  
V,sequences collected by the Kabat data base (Kabat et al., 1991) and combine 
extended primer sets described by Kettleborough et al. (1993). The PCR for the 
production of light and heavy chain genes was optimised and the conditions used are 
described in Section 2.3.4. Bands of light (375 - 402 bp) and heavy (386 - 400 bp) 
chain gene amplification can be seen in Figures 3.7. Results show that the bands for 
both light and heavy chain genes are very clear with minimal production of non- 
specific bands, This is a significant result as production of non-specific bands would 
lower the concentration and diversity of the specific bands and decrease the overall 
diversity of the recombinant library produced using the PCR products. 
The light and heavy chain genes were then assembled together by splice by overlap 
extension (SOE) PCR (Figure 3.8). The SOE-PCR product was purified and digested 
along with the pAKlOO vector. This was followed by ligation of digested SOE-PCR 
product with digested pAK100, as described in Section 2.3.1. Attempts to clone 
digested heavy and light chain SOE-PCR products into the digested pAKlOO vector 
produced low yields of transformants (5 x lo3). However, affinity selection was 
conducted. Selection of scFv antibodies to zilpaterol was carried out by rounds of 
affinity selection panning to enrich for antibodies recognising zilpaterol. Screening of 
positive scFv-producing clones was performed by growing individual colonies 
separately and infecting them with helper phage as described in Section 2.4.1. The 
recombinant scFvs displayed on the surface of the filamentous phage, were tested for 
antigen binding in a typical phage ELISA. This would simultaneously show the 
recognition of scFv for antigen, while also demonstrating extracellular expression if 
culture supernatant were used. 
Four clones found to be positive in phage ELISA were picked from each round of 
panning and further characterised by antigen competition studies to verify that the 
binding was antigen-specific. The clones were A9, B1, E2 and E7 (Figure 3.10). At 
this point B1 was picked for further characterisation and analysis as a soluble scFv in 
order to develop a model system for zilpaterol detection. 
As the B1 clone possesses antigen-specific characteristics as shown by phage display, 
the next step was to produce a soluble scFv antibody. This was carried out by 
digestion of the pAKlOO vector harbouring the light and heavy chain genes of the B1 
clone and sub-cloning into the pAK400 vector for soluble expression in a JM83 cell 
lme. Expression medium devoid of glucose was used to increase expression levels of 
recombinant protein @e Bellis and Schwartz, 1990). The pAK400 vector also 
contains a much stronger Shine-Dalgarno sequence (Krebber et al., 1997), resulting in 
a fixther significant enhancement of protein expression. 
The scFv was then used in the development of a competitive ELISA for zilpaterol. A 
checkerboard ELISA for determination of optimal loading ratios of conjugate and 
optimal anti-zilpaterol scft antibody dilutions was performed and results are shown in 
Figure 3.14. A zilpaterol concentration of 5 ]*g/ml was found to be optimal for use in 
this assay. A model competitive ELISA assay was developed for this antibody in 
PBS where standards of zilpaterol ranging from 4.88 to 10000 ng/ml were prepared 
and mixed with purified antibody at a dilutio~i of 112. The B1 antibody showed a 
limit of detection of 78.13 ng/ml, as approximated fiom Figure 3.15 and Table 3.6. 
Interday assay variability statistics were then analysed in an attempt to look at the 
reproducibility of the assay. Interday assay coefficients of variation (CV's) for the B1 
scFv were found to be between 1.66 to 9.48 %. This result indicated that this anti- 
zilpaterol scFv gives an accurate, specific and reproducible assay. 
The next step was the development of a Biacore-based Inhibition immunoassay for 
the detection of zilpaterol using the B1 anti-zilpaterol scFv. A model inhibition assay 
was developed (described in Section 2.6.5) for free zilpaterol. Standards of zilpaterol 
ranging from 0.98 ng/ml and 1 pglml (fmal concentration) were mixed with 1/10 with 
cellular extract. These mixtures were allowed to incubate at 3 7 ' ~  for 30 minutes 
followed by injection over the zilpaterol-immobilised surface for 3 minutes. The 
antibody response to the surface is inversely proportional to the concentration of free 
drug in solution. These binding responses were plotted in Figures 3.16 and 3.17 and 
show that the detection range of the B1 scFv for free zilpaterol was between 15.6 
n g / d  and 125 nglml. 
Cross-reactivity studies were then performed in order to measure the response of the 
B1 scFv to other beta-agonists and other potential cross reactants. Serial dilutions of 
the cross-reactive analyte of interest are prepared with similar dilutions of specific 
antigen and a competitive ELISA carried out as described in Section 2.2.5. Tables 3.7 
and 3.8 show the ICgO and the ICso values, as calculated using the displacement 
method described by Miller and Valdes (Miller et al., 1992). Competitive assays 
were carried out with several other beta-agonists, in addition to several other potential 
cross-reactants. Clenbuterol, mabuterol, salbutanol and ractopamine (the beta- 
agonists), along with alpha-estradiol, 19-nortestosterone, zeranol, beta-estradiol and 
norethisterone were used in place of zilpaterol in the competitive assay already 
developed. IC90 values, which is the concentration of drug detectable at 90% A/Ao, 
and the ICso values, which is estimated at 50% NAo, for each of these beta agonists 
were calculated (Tables 3.7 and 3.8). 
A comparison between the ranges of detection achieved for assays using the R699 
polyclonal, and the recombinant scFv antibody (Table 3.9) shows that the polyclonal 
antibody demonstrated a higher degree of sensitivity than the scFv antibody. 
Likewise, a comparison between the cross-reactivity percentages calculated for the 
R699 polyclonal antibody, and the recombinant scFv antibody (Table 3.10) 
demonstrates that the polyclonal antibody displayed lower levels of cross reactivity 
compared with the scFv antibody. 
Table 3.9 Comparison befween the range of detection achieved for the R699 Polyclonal Ab and the 
Recombinant scFv antibody 
1 I ELISA (nglml) / Biacore (nglml) I 
Limit of detection Limit of detection 
I I 
Table 3.10 Comparrson between the cross-reactivrty values calculated for the R699 Polyclonal Ab and 
R699 polyclonal Ab 
I I 
Recombinant scFv Ab 
0.24 
the Recombinant scFv antrbody 
0.49 
78 
Drug 
I I I I 
15.6 
Zilpaterol 
Mabuterol 
Ractopamine 
/ a-estradiol I - I - I - 1 - I 
R699 polyclonal Ab 
CR9oC(%) I C R ~ O ~  (%) 
B1 scFv recombinant Ab 
CR9; (%) 1 C R ~ O ~  (%) 
100 
0.1 
- 
Clenbuterol 
Salbutamol 
3 
0.1 
- 
- 
19-nortestosterone 
- 
Zeranol 
100 
- 
- 
P-estradiol 
Norethisterone 
100 
2 
- 
100 
40 
1 
- 
- 
- 
100 
- 
- 
- 
- 
66 
- 
- 
- 
100 
- 
- 
- 
- - 
The antibody fragments described in this chapter are the first recombinant antibodies 
developed against zilpaterol to my knowledge. Further work involving genetic 
engineering of the scFv DNA was planned in order to improve the performance of the 
antibody fragment. However, this work could not be performed as no conjugate was 
available for testing. Comparison of these results with others described in the 
literature was not possible as references to other anti-zilpaterol antibodies could not 
be found. 
Chapter 4 
Cloning, expression and purification of a recombinant form of 
prostate-specific antigen protein 
4.1 Introduction 
4.1.1 Prostate-specific antigen 
Prostate cancer (PCa) is the most frequently occurring cancer affecting men in 
developed countries (Bauvin et al., 2003). Several factors, i.e. genetic, environmental 
and hormonal, are thought to influence the progression of prostate cancer. Despite 
advances in knowledge of various aspects of cancer, an effective treatment for 
prostate cancer has not yet been achieved. Research is, therefore, focusing on 
providing earlier and more accurate detection of the disease (Schmid et al., 2004). 
Prostate-specific antigen (PSA) is a 33kD tissue-specific glycoprotein that belongs to 
the glandular kallilcrein gene family. It was first identified from seminal plasma in the 
early 1970s (Hara et al., 1971) and was subsequently named prostate-specific antigen 
by Wang et al. in 1979. In 1980, it was first identified as present in the serum of men 
with prostate cancer. A group of proteases, the kallikreins, were subsequently 
discovered (Yousef et al., 2001) and to date, 13 separate variants of the protein have 
been identified. All members of the kallikrein family have significant gene sequence 
homologies (Yousef et a l ,  2001). PSA was identified as a member of this family and, 
as such, was given the name human kallikrein 3 (hK3) (Rittenhouse et al., 1998). 
PSA is produced mainly by the prostate gland and its function is thought to be 
liquefaction of seminal fluid through enzymatic action. The active site of PSA is 
closely related to that of the chymotrypsin (Vihinen, 1994). PSA is not a cancer- 
specific protein. Its presence is not unique to cancerous cells, as it is present in 
normal prostate tissue (Jung et al., 2000). Its use as a marker for prostate cancer is 
due to the elevated levels detectable in the serum of prostate cancer patients. Under 
normal conditions, i.e. in non-cancerous tissue, synthesis of PSA by the epithelial 
cells of the prostate gland is directed into the seminal fluid. PSA can only enter blood 
circulation by leaking into the extracellular fluid and diffusing into veins and 
capillaries. However, in cancerous prostatic tissue, turnour growth disrupts the basal 
cell layer and cell polarity is altered. The direction of PSA secretion is disturbed and 
PSA is released freely into the circulatory system. This explains the elevated PSA 
levels in the serum of prostate cancer patients (Stenman et al., 1999). Even though 
prostate cancer cells produce less PSA than non-cancerous cells, more leaks into the 
serum and therefore, elevated serum PSA is detected (Jung et al., 2000). Serum from 
a non-cancer patient contains a PSA concentration of less than 2 pglml. Prostate 
cancer tissue generally contributes about ten times more to serum PSA levels than an 
equal amount of normal prostate tissue (Stamey et al., 1987). Thus, elevated serum 
levels may be indicative of prostate cancer. 
4.1.2 ELISA development for PSA detection 
The practical application of PSA measurement in cancer detection has proved 
problematic. One major factor contributing to this stems from the fact that PSA is not 
a truly cancer-specific marker (Levesque et al., 1995). Various other benign disorders 
have been shown to increase serum PSA levels, and the potential for false positive 
results has diminished the reliability of such PSA assays. One major disorder capable 
of increasing the level of PSA in serum is benign prostatic hyperplasia (BPH) 
(Anderson, 2002). BPH is a non-malignant growth of the prostate gland, 
characterised by similar distortion of the basal cell layer of the prostate gland and free 
release of PSA into blood circulation, as previously described for prostate cancer. 
Current commercially available assays can often fail to distinguish prostate cancer 
from such benign disorders, and, as a result, much research is underway to enhance 
specificity of PSA assays so as to e l i i a t e  the high percentage of false positives. 
The discovery of various forms of PSA in serum, including the presence of 
complexes, has provided a new angle on the proteins role and significance as a 
disease marker in cancer. The predominant fonn of PSA is an al-chymotrypsin PSA 
complex (PSA-ACT), which appears to form 65-95% of the total PSA content of 
human serum (Zhang et al., 1999). Uncomplexed PSA accounts for most of the 
remaining PSA in serum (5-35% of the total PSA content). Other complexes were 
also found to be present in trace amounts, such as PSA-API (a1-protease inhibitor) 
and PSA-AMG (m-macroglobulin). The latter has proven difficult to detect due to its 
lack of immunoreactivity and its presence in serum has yet to be accurately 
quantified. 
Detection of these different forms has proven highly significant since the discovery 
that the relative proportion of complexed to free PSA increases in patients with 
prostate cancer (Christensson et al., 1993). This is thought to be due to the manner in 
which the PSA protein leaks into the blood circulation system. The presence of 
cancerous cells causes disruption of the basal border of the prostate gland epithelial 
cells. This results in loss of the normal secretory pathways and PSA is consequently 
released into the extracellular space and into the circulation. It is believed that this 
process of PSA release enables PSA to encounter and form complexes with ACT and 
AMG (Stenman et al., 1999). Hence, levels of complexed PSA increase relative to 
kee PSA in the serum of cancer patients. This information indicates a potential 
discriminatory factor that can be incorporated into PSA assays to increase specificity 
for prostate cancer detection. If specific antibodies against free and complexed forms 
of PSA could be developed and used in a prostate cancer assay format, then the 
potential of eliminating false positive results from benign disorders such as BPH is 
possible. 
PSA is still recognised as the best available indicator for the presence of prostate 
cancer (Sarkar, 2002). Before the distinction between the various forms of PSA (i.e. 
fkee and bound forms) was established as an important factor in prostate cancer 
detection, antibodies generated did not distinguish between such forms, and the 
ELISAs developed detected total PSA levels only. The fust immunoassay for PSA 
was described in 1980 (Kuriyama et al., 1980). The format was a sandwich ELISA 
which was sufficiently sensitive to detect PSA in the serum of normal men and 
patients with BPH and prostate cancer. Following this, a sandwich ELISA was 
developed that detected total PSA only (Stowell et al., 1991). Another sandwich 
ELISA used a polyclonal anti-PSA antibody coated to the surface of the ELISA plate 
for capture, and a monoclonal anti-PSA antibody, conjugated to HRP, for detection of 
total PSA (Khosravi et al., 1995). Better sensitivity and accuracy was achieved. A 
limit of detection of 0.009 d l  was reported. Assays evaluating the cross-reactivity of 
10 anti-PSA monoclonal antibodies with the human Kallikrein 2 (hK2) were also 
conducted. These assays consisted of a sandwich ELISA and western blot transfer 
techniques. No cross-reactivity was observed in western blot analysis when hK2 was 
probed with anti-PSA antibodies. ELISA analysis concluded that 8 out of 10 
antibodies analysed demonstrated cross-reactivity between PSA and hK2. However, 
no combination of monoclonal antibodies tested in a sandwich ELISA for hK2 could 
give a sigual comparable to that for PSA in the same assay. The signal observed for 
hK2 was no greater than 0.1% of the PSA signal. It was concluded that despite the 
80% sequence homology between PSA and hK2, a sizable subset of the immunogenic 
regions consist of surface epitopes that present either different amino acid residues or 
distinguishing tertiary structures in the two antigens. The determination of PSA 
levels using a sandwich ELISA would, therefore, not be significantly affected by 
cross-reactivity. (Corey et al., 1997). 
An ELISA capable of detecting the levels of uncomplexed, free PSA in serum was 
first reported in 1999 by Matsumoto et al. A range of monoclonal antibodies against 
PSA was first generated and two were selected. One was specific for free PSA and 
the other for both the free and complexed forms. Both were used to develop an 
ELISA for free PSA. The detection limit for free PSA established for this assay was 
0.008 pgll for complexed PSA. A year later, the same group published details of an 
ELISA detecting a complexed form of PSA, PSA-eel-anti-chymotrypsin. (Matsumoto 
et al., 2000). Three different monoclonal antibodies that recognised three distinct PSA 
epitopes were used in the ELISA. Two of the three monoclonal antibodies recognised 
two specific epitopes on the surface of total PSA, i.e. recognised the PSA protein 
regardless of whether it was free or complexed. The third antibody recognised an 
epitope only exposed on free PSA. Binding of this third antibody inhibited binding of 
the fmt  two by blocking access to the epitopes to which they would bind. In this 
way, free PSA detection by the assay was blocked and a sandwich ELISA for the 
detection of complexed PSA was conducted using the other two monoclonal 
antibodies. This ELISA reported a detection limit of 0.19 pgll. The result of this data 
is that commercial assays are now available that discriminate between eee  and bound 
forms of PSA. However, studies have shown significant differences in the 
sensitivities of these assays, indicating a lack of reliability (Oberpenning et al., 2002). 
It is for this reason that current research is still intensely focused on the development 
of more reliable and accurate assays for the presence of prostate cancer. 
One aspect of such research is the development of immunoassays that can 
demonstrate higher specificities to the various forms of PSA. Free PSA, is now 
known to consist of several slightly varying forms, including intact PSA (consisting 
of proPSA and inactive PSA), internally cleaved PSA, and several other newly 
identified forms (Mikolajczyk et al., 1997; Peter et al., 2001). Studies indicate that 
assays able to specifically detect these forms could provide M e r  accuracy in 
discriminating prostate cancer from benign disorders. Researchers in the University 
of Turku in Finland are currently developing immunoassays against various forms of 
cancer-relevant free PSA. In 2000, Nunnikko et al. produced a PSA-specific 
monoclonal antibody that did not detect the internally cleaved form of PSA. Epitope 
mapping, peptide mapping, specificity, binding and affinity studies were conducted 
on these antibodies. A year later, the same group reported the development of an 
immunofluorometric sandwich assay for the measurement of intact, free PSA, but not 
internally cleaved forms (Nurmikko et al., 2001). The detection limit of this assay 
was determined to be 0.035 pgn. A similar immunofluorometric assay was also 
developed using europium (111) chelate nanoparticles. The detection l i t  achieved 
with assay was 0.04 ng/l. Because of the low sensitivity demonstrated, further 
optimisation of this assay is planned (Soukka et al., 2001). To date, limited research 
seems to indicate that the ratio of internally cleaved to normal forms of PSA decreases 
in the serum of cancer patients. Hence, an immunoassay capable of quantifying these 
forms could potentially increase the accuracy of detection of prostate cancer. 
Immunoassays utilising antibody fragments for the detection of PSA in serum have 
also been produced. Recombinant Fab fragments capable of detecting both free and 
complexed PSA have been reported (Eriksson et al., 2000). The capture Fab, which 
bound both free and complexed PSA, was biotinylated and attached to streptavidin- 
coated mictrotitre wells. A Fab fragment that detected only free PSA, was labelled 
with a fluorescent europium chelate while a Fab detecting both free and complexed 
PSA was labelled with fluorescent terbium. Time-resolved fluorescence was used to 
measure both the europium and terbium signals in one well. Development of an 
immunoassay with europium- or terbium-labelled Fab fragments provided comparable 
results to assays conducted using monoclonal anti-PSA antibodies. Detection limits 
of 0.043 and 0.28 pg/l for both hee and total forms of PSA were achieved. 
Recombinant Fab fragments have also been used to capture and detect free and total 
prostate-specific antigen from serum in a single-particle immunoassay (Harma et al., 
2000). Thiol-Fab or thiolated monoclonal antibodies were covalently attached onto 
activated microparticles and free and total PSA were detected with europium- or 
terbium-labelled Fab fragments on a single microparticle using a microfluorometer. 
The limit of detection achieved was 0.35 pg/l. 
Time-resolved fluorescence imaging was used for the immunohistochemical detection 
(i.e. tissue samples) of PSA and hK2 using lanthanide chelate-labelled monoclonal 
antibodies. Comparisons of the results obtained for both PSA and hK2 showed that 
signal intensity for PSA and hK2 correlated in benign tissue, while variation was 
observed in these signals between benign and malignant samples. This indicated that 
the assay is capable of comparing PSA and hK2 content in individual cells, and could 
potentially be used to indicate the presence of prostate cancer (Siivola et al., 2000). 
The cloning, expression and purification of a recombinant form of prostate-specific 
antigen protein is described in this chapter as very little work was reported in the 
literature for development of free and total PSA assays using antibody fragments. 
The PSA gene was inserted and expressed in E. coli cells. The PSA protein was 
purified by IMAC. A preliminary investigation of the feasibility of the use of a 
competitive ELISA for determining the concentration of PSA that was cloned and 
expressed as part of the research, was undertaken. 
4.2 Results 
4.2.1 Transfer of PSA gene insert into pQE-60 vector. 
A vector was obtained from Dr. Evaggelia Emmanouilidou fiom the Laboratory of 
Analytical Chemistry, Department of Chemistry, University of Athens, Greece 
(Emmanouilidou et al., 2002) that contained the PSA gene insert. The vector, 
psa.pcDNA3, was used to transform competent JM83 cells, and several positive 
transformants were selected and cultures of these grown. The plasmid was then 
isolated Gram these cells, the gene encoding the PSA protein was restricted from the 
psa.pcDNA3 vector and PCR amplified using specifically designed primers (Figure 
4.1). The PSA gene bands as well as the pQE-60 vector were restricted with BamHl 
and Ncol Figure 4.2) and re-ligated into the high level expression vector, pQE-60. 
The ligated PSA gene and pQE-60 vector were then transformed into competent XL- 
10 Gold E. coli for controlled protein expression. Glycerol stocks of the resulting 
transformants were made and stored at -80'~. 
PCR- 
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PSA gene 
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Figure 4.1 Gel picture showing 850 bp bands containing the ampliJed PSA gene. Lanes I and 6 
represent a Promega 1 Kbplus DNA ladder Lanes 2-5 represent DNA coding for PSA. 
Digested 
pQE-60 ' 
vector 
, Restricted 
PSA gene 
Figure 4.2 BamHl and Ncol restriction digest of the PSA gene and the pQE-60 vector. Lane 1 
represents a Promega 1Kb DNA ladder. Lane 2 contains restrictedpQE-60 vector. Lane 3 contains 
the restricted PSA gene. 
- 
4.2.2 Reamplification of PSA gene, ligation into pQE-60 and transformation into 
XL-10 Gold 
Overnight cultures of the glycerol stocks already produced were made and the pQE- 
60 vector containing the PSA gene insert was isolated. This was then used as a 
template for another PCR amplification of the PSA gene using the newly designed 
primers (Figure 4.3). The newly amplified PSA gene was restricted with Sfil along 
with the pQE-60 vector (Figure 4.4) ligated and transformed into X - 1 0  Gold cells. 
PCR- 
amplified 
PSA gene 
Figure 4.3 Gel picture showing 850 bp bands contarning the amplfied PSA gene a@er PCR has been 
conducted using the newly desrgnedprirners. Lane I represents a Promega I Kb plus DNA ladder 
Lanes 2 and 3 represent DNA coding for PSA. 
PQE-60 vector 
Gene insert 
PSA gene 
Figure 4.4 S'I restriction digest of the nwly-ampl$ed PSA gene and the pQE-60 vector. Lane I 
contains restricted pQE-60 vector. Lone 2 contains the restriction digested PSA gene. Lane 3 
represents a Promega 1Kb DNA ladder. 
4.2.3 Time course analysis of PSA expression 
Once PSA expression fiom the transformed XL-I0 Gold cells (prepared as in Section 
2.3.8) had been confirmed, a time course analysis on the level of protein expression 
was conducted to determine the optimal induction time for protein expression. This is 
important in order to get the balance between the amount of soluble protein in the 
cells, the formation of inclusion bodies, and protein degradation. By checking the 
recombinant protein present at various times after IPTG induction, the optimal 
induction period can be established. A 50 ml culture of the transformed XL-10 Gold 
cells in log phase was inoculated with IPTG and expression of PSA was induced. 1 
ml samples were taken at one-hour intervals for up to 5 hours, and then following 
overnight induction. The cytoplasmic extract was isolated fiom each sample and 
SDS-page analysis was carried out (Figure 4.5). Western blot analysis was then 
conducted on alternate samples (i.e. sample T=O, T=2, T=4 and T=overnight) with the 
protein bands probed with a PSA-specific polyclonal antibody (Figure 4.6). 
PSA protein 
29kDa 
Figure 4.5 Time-course expression of PSA in Z - 1 0  Gold cells. Lane 1 contains molecular weight 
markers for protein qua1iJ;cation Lane 2 represents protein expression I hour afrr induction, lane 3 
after 2 hours, lane 4 after 3 hours, lane 5 aftr  4 hours, and lane 6 affr  overnight induction. A band 
at 29 kDa is visible and is mostprominent after 4 hours of induction. 
PSA 
Figure 4.6 Western blot analysis of time-course expression of PSA inXL-10 Gold cells. Lane 1 is the 
PSApresent 2 hows after induction. Lane 2 is the PSA present 4 hours af fr  induction. Lane 3 is the 
I 
I PSA presence af tr  overnight induction Lane 4 containsprestained molecular weight markers. 
4.2.4 lmmobilised metal affinity chromatography @MAC) purification of PSA 
The MAC purification technique was used to obtain a purified form of the PSA 
protein from the cytoplasmic extract, which contains a large number of contaminating 
proteins in addition to the PSA that have been produced by the host cell. Purification 
of PSA was conducted under denaturing conditions using IMAC resin supplied by 
QIAgen. The purified fractions were analysed by SDS-PAGE (Figure 4.7) and 
Western Blot (Figure 4.8) techniques. 
PSA 
Figure 4.7 SDS-PAGE analysis on the lM4Cpurifcation of PSA. Lane 1 is crude cytoplasmic lysate 
j k r n  XL-10 Gold follaving PSA expression. Lane 2 is jlow-through from IM4C column following 
application of crude lysate. Lanes 3 and 4 are fractions collectedfrom washings of the column Lanes 
5, 6 and 7 are column elutions 1, 2 and 3, respectively. A band PSA is visible in each of the 3 elutions. 
PSA 
Protein 
Figure 4.8 Western blot analysis on the IMACpuriJication of PSA. Lane I is crude cytoplasmic lysate 
from XL-10 Gold following PSA expression. Lane 2 is Pow-through from IMAC column following 
application of crude lysate. Lanes 3 and 4 me washfracflions 1 and 2, respectively. Lanes 5, 6 and 7 
are elzitions 1, 2 and3, respectively. Lane 7 contains molecular weight markers. 
4.2.5 Development of a competitive enzyme-linked immunosorbent assay 
(ELISA) for PSA 
A competitive ELISA was developed for the detection of the recombinant form of 
PSA using the commercial rabbit-anti-PSA polyclonal antibody. In order to 
determine the inter-day assay variation, the ELISA was repeated three times over 
three separate days. The normalised mean values, which were calculated as the mean 
absorbance at each antigen concentration 1 absorbance in the presence of zero antigen 
concentration (AIAO) over the three days were used to construct a calibration curve 
for the interday assay. Using Biaevaluation 3.1 software the calibration curve was 
plotted using the four-parameter equation. 
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Figure 4.9 Inhibition ELISA for recombinant PSA 
Table 4.10 Percentage CVvalues calculated for the inhibition ELISA for recombinant PSA plotted m 
Figure 1 
PSA dilution 
1 12 
1 14 
118 
1/16 
1/32 
1/64 
11128 
11256 
11512 
% CV 
9.40% 
10.76% 
8.56% 
6.46% 
8.92% 
8.47% 
5.15% 
6.76% 
0.40% 
This Section describes the successful cloning, expression and purification of PSA. 
The PSA gene insert was received in the psa.pcDNA3 vector, which was initially 
transformed into JM83 E. coli cells to allow for plasmid isolation and restriction of 
the vector for isolation of the PSA gene. The gene was then amplified by PCR, 
restricted and ligated into a fully purified and restricted pQE-60 expression vector. 
The vector was subsequently transformed into XL-10 Gold cells for soluble 
expression. 
Expression of the PSA protein was initially analysed by conducting a time-course 
expression study. Clones were induced with IPTG for soluble PSA expression and 
samples taken every hour for 4 hours and then after overnight induction to analyse the 
optimal expression time. The results of this was analysed by SDS-PAGE and 
Western blot analysis. It was determined that 4 hours of induction was the optimal 
length of time after which PSA was to be isolated. The results of IMAC purification 
were also analysed by SDS-PAGE and Western blot, and purified PSA was visible 
when the elution fractions of the purification were observed. 
Further work regarding purification was not possible due to the time constraints of 
this project. Future work in this area would involve further optimisation of the 
conditions for protein expression and purification, in order to obtain a pure, 
concentrated sample of PSA protein for analysis. 
In addition, due to time constraints, only a basic investigation using recombinant PSA 
protein which was not possible to quantify, could be performed to determine if a 
competitive ELISA would demonstrate the required competition. Dilutions of the 
neat stock of recombinant PSA were used to perform the investigation (Section 4.2.4). 
A plot of the initial inhibition ELISA performed using commercial anti-PSA 
antibodies shows a definite inhibition trend (Figure 4.9). Since this work consists of 
only initial investigation into the development of a competitive immunoassay for 
PSA, finther work in this area would involve quantification of purified recombinant 
protein, and development of sensitive ELISA and Biacore-based inhibition assays. 
Future work could also involve use of the recombinant PSA protein for the 
immunisation and subsequent development of scFv antibody fragments, using the 
I methods outlimed in Section 2.2 to 2.4 for the development of such fragments to 
zilpaterol. Such antibody fragments would then be used to develop Biacore-based 
inhibition assays to PSA. 
Chapter 5 
Qverall Conclusions 
5.1 Overall conclusions 
The research work described in this thesis is mainly concerned with the development 
of scFv antibody hagments and the use of these fragments along with polyclonal 
antibodies for the detection of the beta-agonist zilpaterol, and prostate-specific 
antigen (PSA). 
The initial work carried out in this thesis was the characterisation of a polyclonal 
antibody for zilpaterol, provided by Dr. Lisa Connolly of Queens University, Belfast. 
The antibody was used to develop a competitive ELISA for the detection of zilpaterol. 
This assay involved immobilisation of the polyclonal antibody onto the surface of a 
microtitre plate, then simultaneous addition of a fixed concentration of HRP-labelled 
zilpaterol and varying concentrations of free zilpaterol. The signal produced was 
inversely proportional to the concentration of fiee zilpaterol present in the assay. A 
model competitive assay was developed which displayed excellent recognition of the 
unconjugated zilpaterol molecules and showed very low limits of detection. The 
interday assay variability statistics were determined. Cross-reactivity studies were 
also performed in order to assess the reactivity of the assay with structurally similar 
molecules. Competitive assays were carried out with several other beta-agonists, in 
addition to several other potential cross-reactants. Analysis of these results indicates 
that use of this polyclonal antibody gives an accurate specific and reproducible assay. 
The next step was the development of a Biacore-based inhibition immunoassay for the 
detection of zilpaterol using R699 anti-zilpaterol polyclonal antibody. The binding 
response demonstrated showed very low limit of detection, indicating a highly 
sensitive assay. 
The next section of the research was the successful production of an scFv antibody 
fragment specific for zilpaterol and use of this fragment in the development of an 
assay for the detection of zilpaterol. Libraries produced from pre-immunised spleen 
mRNA were subjected to rounds of affinity selection panning to select for and enrich 
for antibodies recognising zilpaterol. The scFv demonstrating the best biding 
characteristics was then expressed and used in the development of a competitive 
ELISA for zilpaterol. 
A Biacore-based Inhibition immunoassay for the detection of zilpaterol using the B1 
anti-zilpaterol polyclonal scFv was also generated. Cross reactivity studies were also 
conducted using Biacore to measure the response scFv to other 0-agonsits and other 
potential cross-reactants. 
Results showed that the assay developed was repeatable and reliable, and while 
improvement of the affinity of the scFv would result in a more sensitive assay, the 
ability of the scFv antibody to be used in such an assay format was confirmed. 
However, the antibody could be improved by established genetic engineering 
approaches. 
Chapter 4 details the successful cloning, expression and purification of PSA. The 
results of a competitive ELISA for the detection of the recombinant form of PSA 
using the commercial rabbit anti-PSA polyclonal antibody are also described. While 
the concentration of the PSA protein used in the dilution could not be determined 
accurately, a plot of the results obtained indicated that the development of an 
inhibition ELISA using the recombinant form of the PSA is feasible. 
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